

On the cover (left to right):

Top row
JOSÉ BASELGA, MD, PHD, FAACR
The AACR President for 2015-2016, Dr. Baselga is Physician-in-Chief at Memorial Sloan Kettering Cancer Center, New York, New York.

CARLOS L. ARTEAGA, MD, FAACR
The AACR President for 2014-2015, Dr. Arteaga is Director of the Center for Cancer Targeted Therapies and the Breast Program and SPORE at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.


Bottom row
SERGIO RAMIREZ
Diagnosed with acute lymphoblastic leukemia, Sergio participated in a clinical trial and is beating the disease thanks to the immunotherapeutic blinatumomab.

JAMEISHA BROWN
Diagnosed with cancer at the age of eight, Jameisha has been cancer-free for 17 years and now conducts research on cancer health disparities.

LORI CUFFARI
Since starting lenvatinib, Lori's Hurthle cell cancer is no longer visible and she is living a normal life, eating what she wants, and looking forward to the future.



BRINGING CANCER DISCOVERIES TO PATIENTS



Immunofluorescence confocal microscopy image of an immunostained whole mount preparation of the dorsal mouse ear dermis. Swartz, M.A. Cancer Immunology Research August 2014 2:701-707.

CONTENTS

MISSION AND VISION	1
WELCOME: BRINGING CANCER DISCOVERIES TO PATIENTS	2
PROGRESS AGAINST CANCER IN 2015	4
ANNUAL MEETING	6
AACR INTERNATIONAL	12
HONORING SCIENTIFIC ACHIEVEMENT	14
SCIENTIFIC PUBLISHING	18
SCIENCE AND EDUCATION	22
SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION	28
GOVERNMENT AFFAIRS / SURVIVOR AND PATIENT ADVOCACY	32
MEMBERSHIP	36
LEADERSHIP	40
AACR FOUNDATION	46
FINANCIAL STATEMENT	56
THE AACR IN 2016: A LOOK AHEAD	58

MISSION

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

VISION

To be the most effective catalyst for cures and prevention through cancer science.

HISTORY

The AACR is the world's first and largest cancer research organization dedicated to accelerating the prevention and cure of cancer. Founded in 1907 by nine physicians and two laboratory scientists, the AACR has more than 35,000 members in 101 countries. Learn more about the history of the AACR at AACR.org/history.

Follow us:      AACR.org

WELCOME BRINGING CANCER DISCOVERIES TO PATIENTS

We are pleased to present the 2015 Annual Report of the American Association for Cancer Research (AACR). The report highlights the AACR's progress over the past year in support of our mission: to prevent and cure cancer through research, education, communication, and collaboration.

The theme of the AACR Annual Meeting 2015, "Bringing Cancer Discoveries to Patients," is also the theme of this report. It emphasizes the critical value of each step along the cancer science continuum, from basic discoveries to translational advances to clinical treatments. With 35,000 members working in every discipline along that continuum, the AACR is uniquely positioned to improve the lives of cancer patients in a myriad of ways:

Research

The AACR identifies and fosters innovative science that is of the highest priority for impact in reducing cancer incidence, morbidity, and mortality. One of the AACR's major mechanisms for accomplishing this goal is to promote high-quality science through its Scientific Review and Grants Administration program. The AACR provides scientific oversight and expert peer review to ensure that the most promising projects receive essential funding. Working with funding partners throughout the cancer community, the AACR awarded nearly \$70 million in grants to exceptional investigators in 2015. The AACR also fosters innovation and recognizes the meritorious work of investigators and their impact on the field through Scientific Achievement Awards and election as Fellows of the AACR Academy.

Education

The AACR sustains the pipeline of cancer scientists at all career levels. Special programs inspire high school students and undergraduates to pursue careers in cancer research, and educational workshops teach early-career scientists to become leaders in their fields. AACR Annual Meetings and conferences bring together emerging and established scientists to share their research findings and learn about the latest developments in all disciplines. The AACR also educates advocates through its highly regarded Scientist↔Survivor Program, pairing them with mentors who provide the scientific context for their vitally important work in the cancer field.

Communication

The AACR's scientific journals and conferences provide leading investigators with a vital forum for sharing the latest discoveries, using the page and the podium to disseminate cutting-edge cancer science in all disciplines. The AACR also fosters dialogue among the various stakeholders in the cancer community. Through briefings, workshops, and the AACR Cancer Progress Report, the Office of Science Policy and Government Affairs keeps lawmakers, regulators, and the public informed about the critical value of cancer research. In addition, *Cancer Today* magazine and the

Survivor and Patient Advocacy program provide authoritative knowledge that empowers patients, caregivers, and patient advocates to meet the challenges of a cancer diagnosis.

Collaboration

With members in 101 countries and a longstanding reputation for scientific excellence, the AACR forges partnerships with scientific and advocacy organizations worldwide to advance science for the benefit of all cancer patients. In addition, the AACR's cross-disciplinary meetings, workshops, and task forces bring investigators from academia, government, and industry together, breaking down silos and building productive relationships.

Cancer is a complex disease, and achieving our mission to prevent and cure all cancers requires a concerted effort in a wide range of scientific and policy areas. As this report demonstrates, the AACR is actively engaged in these areas, supporting the community that will translate our increasing understanding of the cancer problem into solutions.

OUR MISSION IS AMBITIOUS. TOGETHER, WE WILL ACHIEVE IT.



Left to right:
José Baselga, MD, PhD, FAACR
AACR President 2015–2016
Margaret Foti, PhD, MD (hc)
AACR Chief Executive Officer
Carlos L. Arteaga, MD, FAACR
AACR President 2014–2015

PROGRESS AGAINST CANCER IN 2015 POWERED BY RESEARCH

Research increases understanding of the collection of diseases known as cancer and allows the translation of knowledge into new and increasingly precise ways to prevent, detect, diagnose, treat, and cure many of these diseases. In 2015 alone, research fueled U.S. Food and Drug Administration (FDA) approval of 16 new anticancer therapeutics and seven new uses for previously approved anticancer therapeutics.



Renata Pasqualini, PhD (right) and her husband Wadih Arap, MD, PhD (left) in their joint laboratory at the University of New Mexico Comprehensive Cancer Center. An AACR Career Development Grantee, Dr. Pasqualini was motivated to pursue a career in medical research by her mother's breast cancer diagnosis and successful treatment.

Nine of the newly approved drugs — alectinib (Alecensa), cobimetinib (Cotellic), daratumumab (Darzalex), elotuzumab (Empliciti), lenvatinib (Lenvima), necitumumab (Portrazza), osimertinib (Tagrisso), palbociclib (Ibrance), and sonidegib (Odomzo) — target specific molecules involved in cancer and are referred to as molecularly targeted therapeutics. They are part of the precision medicine revolution that is ensuring that more people are living longer, higher-quality lives after a cancer diagnosis.

Four of the newly approved drugs — daratumumab (Darzalex), dinutuximab (Unituxin), elotuzumab, and talimogene laherparepvec (Imlygic) — work by harnessing the power of a patient's own immune system to fight his or her cancer, which demonstrates the emergence of cancer immunotherapy as a key pillar of care. The power of cancer immunotherapy lies in the remarkable and durable responses experienced by patients with a variety of types of cancer.

The American Association for Cancer Research (AACR) is proud to have helped catalyze the progress made against cancer in 2015 through its many programs, services, and initiatives. For example, early results from the clinical trial that led to the October 2015 FDA approval of the immunotherapeutic pembrolizumab (Keytruda) for treating certain patients with non-small cell lung cancer were first disseminated at the AACR Annual Meeting 2015.

With one in two men and one in three women in the U.S. expected to be diagnosed with cancer in their lifetimes, it is vital that the AACR communicates the spectacular advances against cancer to all sectors of the American population. The annual AACR Cancer Progress Report is a cornerstone of the AACR's efforts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the FDA.

The AACR *Cancer Progress Report 2015* chronicles how federally funded research spurred progress against cancer in 2015 and showcases the fact that the number of FDA-approved molecularly targeted anticancer therapeutics more than doubled in the past five years.

As AACR President (2015–2016) José Baselga, MD, PhD, FAACR, stated in the report, “...these are exciting times and... the pace of discovery and application of new knowledge to patient care is rapidly accelerating.”

“...these are exciting times and...the pace of discovery and application of new knowledge to patient care is rapidly accelerating.”

— José Baselga, MD, PhD, FAACR

Right: Survivors featured in the AACR Cancer Progress Report 2015. The annual AACR Cancer Progress Report is a cornerstone of the AACR's efforts to increase public understanding of cancer and the importance of cancer research to public health, and to advocate for increased federal funding for cancer research.



ANNUAL MEETING

ANNUAL MEETING CROSSROADS OF THE CANCER COMMUNITY

All of the stakeholders in cancer research come together at the AACR Annual Meeting. The 2015 Annual Meeting was the largest in history, with over 19,300 scientists, clinicians, patients, and advocates from 71 countries gathered in the AACR's home city of Philadelphia to share the latest cancer science.

Sharing Scientific Knowledge

Basic and translational scientists and clinical investigators convened at poster boards and podiums to present the full spectrum of cancer discoveries.

Mentoring Future Innovators

Leaders in all fields fostered the next generation of cancer researchers, engaging with high school students, undergraduates, and early-career scientists in career development sessions to offer inspiration, encouragement, and practical advice.

Navigating Regulatory Science

Academic and industry scientists interacted with regulatory agencies in Regulatory Science and Policy sessions, fostering dialogue and accelerating the discovery and development of new diagnostics and treatments.

Educating Survivors and Advocates

In the AACR's Scientist↔Survivor Program, scientists provided survivors and advocates with a vital scientific context for the discoveries presented. In turn, survivors and advocates provided a critical patient perspective for scientists to bring back to their laboratories and clinics.



ANNUAL MEETING SETTING THE RESEARCH AGENDA

The theme of the Annual Meeting, *Bringing Cancer Discoveries to Patients*, underscored the link between discovery and treatment. The multidisciplinary program included researchers from across the continuum of cancer science, from population science, to basic, translational, and clinical cancer research. Highlights of the cutting-edge research presented at the meeting were summarized by AACR leaders in a closing plenary session.



During the closing plenary, **Lewis C. Cantley, PhD, FAACR, chairperson of the 2015 Annual Meeting Program Committee**, discussed key basic research presentations. These included numerous studies investigating genetic diversity among different cells isolated from a single tumor and among tumors isolated from different sites in a single patient. He emphasized the critical value of mapping this genetic heterogeneity and understanding how it evolves because the information is vital to understanding and overcoming treatment resistance. Cantley also highlighted presentations that revealed mechanisms of resistance to specific molecularly targeted therapies and how a combination of basic research approaches — including proteomics, systems biology, organoids, and CRISPR-Cas9 technology — are being used to overcome this challenge and catalyze the development of new targeted therapies.



the groundbreaking clinical and translational research presented at the meeting. He began with several studies on

an immunotherapy approach known as checkpoint blockade, including two that subsequently led to approvals by the U.S. Food and Drug Administration (FDA). The first study was the phase III clinical trial presented in the Opening Plenary session by Antoni Ribas, MD, PhD, which showed that pembrolizumab (Keytruda) yielded significantly better outcomes than ipilimumab (Yervoy) when it was the first treatment given to patients with advanced melanoma. These results later led the FDA to approve the use of pembrolizumab for use in this setting. The second practice-changing study was presented by Stephen Hodi, MD, who showed that giving the two immunotherapies ipilimumab and nivolumab (Opdivo) simultaneously yielded better treatment responses than ipilimumab alone for patients with advanced melanoma who had received no prior treatment. These data and follow-up analysis led the FDA to approve this immunotherapy combination in late September.

Artega then highlighted several studies in the area of predictive genomics — the use of genomics to identify those patients most likely to respond to a particular therapeutic. Recalling the challenges of tumor heterogeneity discussed by Cantley, he stressed the importance of collecting genomic information from more than one site of metastasis. Artega closed with a discussion of several presentations detailing the potential of liquid biopsies as a viable alternative to tumor tissue biopsies for genomic analysis.




William G. Nelson, MD, PhD, editor-in-chief of *Cancer Today*,

highlighted key presentations on cancer prevention research, in particular those in the emerging field of precision prevention and early detection. He initially focused on studies developing and using molecular tools for screening and early detection, such as the DNA stool test for colorectal cancer, and went on to discuss the use of genomics to identify individuals who are at highest risk for certain cancers and might benefit from chemoprevention approaches such as taking aspirin for colorectal cancer prevention. Nelson concluded his summary with studies suggesting that the microbiome has an important role in cancer biology, focusing on preclinical data showing that a particular bacterium promotes colorectal cancer development in a mouse model of the disease.



José Baselga, MD, PhD, FAACR, AACR president 2015–2016, concluded the session

with a vision for the future — a future in which the promise of precision medicine, immunotherapy, and the harnessing of big data is fully realized.



Tyler Jacks, PhD, FAACR, discusses applications of the CRISPR-Cas9 system in cancer biology during his presentation on “Engineering the cancer genome” at the Opening Plenary Session of the AACR Annual Meeting 2015.



ANNUAL MEETING AT A GLANCE

Record-setting Number of Attendees in Philadelphia

19,300

People attended the meeting. The Annual Meeting 2015 was the largest in the history of the AACR.

71

Countries were represented at the meeting.

5,820

Papers were presented in poster sessions or minisymposia.

A Dynamic Scientific Program Highlights Cutting-edge Clinical Research

101

Clinical trials were presented at the meeting, including a phase III study of pembrolizumab versus ipilimumab in patients with advanced melanoma. Featured in the opening plenary session, the randomized trial was the first to compare two FDA-approved immune checkpoint inhibitors as first-line therapy. The results of the study indicate that pembrolizumab yielded significantly better outcomes than ipilimumab, which is the current standard of care.

Presentation of the trial was followed by a discussant, who placed the clinical results in biological context for an audience that spanned the continuum from basic to translational to clinical scientists. Because of the AACR's unique ability to bring together the full spectrum of cancer investigators, clinical trials presented at the AACR Annual Meeting go beyond changing practice; they also advance the science.

783

Scientists participated as invited speakers, sharing their expertise and their data with the cancer community.

244

Scientific sessions provided a diverse forum for leading investigators, including **48 major symposia** and **five plenary sessions**. For the first time in 2015, the meeting featured a **closing plenary session** that summarized the key themes of the meeting and offered a vision of the future, providing attendees with a first draft of the research agenda for the coming year.

1,228

Physician scientists and clinicians claimed Continuing Medical Education (CME) credit for attending the meeting. The AACR has offered CME credit for Annual Meeting attendees since 1983.



ANNUAL MEETING GENERATING TOP-TIER MEDIA COVERAGE

The AACR Annual Meeting 2015 produced a record amount of news coverage and social media interest, strengthening the organization's brand as the authoritative voice and resource in cancer research.

Media Impact

50

News releases were distributed.

166

Reporters attended.

2,100+

Media stories were generated.

19,176

Tweets mentioned the Annual Meeting.

4,245

Tweets referenced the #AACR15 hashtag — which trended at #1 worldwide on Sunday, April 19.

406

Scientists, clinicians, patients, and advocates, participated in the second annual ABC News Twitter chat from the Annual Meeting — including the AACR's first live broadcast on Periscope.

2,300

Tweets were sent during the chat.

Among the many news organizations covering the Annual Meeting were the following major media outlets:

THE WALL STREET JOURNAL

AP

TIME



Forbes

REUTERS

Bloomberg

CNBC

THE HUFFINGTON POST



AACR INTERNATIONAL ADVANCING CANCER SCIENCE AROUND THE WORLD

Cancer knows no boundaries. Neither does the AACR. Thirty percent of AACR members are located outside the U.S. With a member presence in 101 countries — and with satellite offices in Canada and China — the AACR reaches across national borders to promote scientific excellence, working with numerous organizations to provide forums for cutting-edge research from around the world. Through scientific conferences, educational workshops, and financial support, the AACR ensures that the cancer research community is as geographically diverse as the patients it serves.


New Horizons Conference Series Continues

The second edition of the conference on New Horizons in Cancer Research was held in Shanghai, China, in November 2015. Co-chaired by AACR President Carlos L. Arteaga, MD, FAACR, and Annual Meeting Program Chairperson Lewis C. Cantley, PhD, FAACR, the program combined highlights from the AACR Annual Meeting 2015 with presentations from international speakers and local experts to cover the full spectrum of cancer research.

International Collaborations Foster Innovative Science

Working with international scientific organizations, the AACR organized six joint conferences and workshops in 2015:

- EACR-AACR-SIC Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic, Florence, Italy, June 2015
- ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, Flims, Switzerland, June 2015



Attendees participate in a poster session at the AACR/Cold Spring Harbor Asia conference on Big Data, Computation, and Systems Biology in Cancer, held in December 2015 in Suzhou, China.

- CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, New York, September 2015
- AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, November 2015
- AACR/Cold Spring Harbor Asia Conference on Big Data, Computation, and Systems Biology in Cancer, Suzhou, China, December 2015

Emerging Partnerships Bring Cutting-edge Science to New Audiences

AACR-sponsored sessions at international meetings in 2015 included the following:

- Pre-conference workshop on “Follicular Lymphoma: Recent Insights and Future Directions” and two lectures, 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2015
- “Precision Medicine,” African Organization for Research and Training in Cancer (AORTIC) Annual Meeting, Marrakech, Morocco, November 2015



Exchanging Ideas, Building Relationships

The AACR further strengthened its relationship with the Chinese Society of Clinical Oncology (CSCO) in 2015, organizing joint sessions at the annual meeting for each organization:



- “Using Genome Sequencing to Identify Responders to Targeted and Immune Therapeutics,” AACR Annual Meeting, Philadelphia, Pennsylvania, April 2015
- “Lung Cancer,” CSCO Annual Meeting, Xiamen, China, September 2015

HONORING SCIENTIFIC ACHIEVEMENT



The success of the AACR's mission to prevent and cure cancer depends upon an appreciation of the past and a vision of the future. It requires an understanding of the critical discoveries that have shaped the current scientific paradigm as well as the wisdom and foresight to shift that paradigm when necessary.

The induction ceremony for the 2015 class of Fellows of the AACR Academy took place at the Franklin Institute in Philadelphia during the AACR Annual Meeting 2015.

FELLOWS OF THE AACR ACADEMY RECOGNIZING SCIENTIFIC ACCOMPLISHMENT

Established in 2013, the AACR Academy recognizes and honors distinguished scientists whose contributions have consistently propelled significant innovation and progress against cancer. While election as a Fellow of the AACR Academy (FAACR) is a great honor for current accomplishments, it is also an opportunity to guide the future of cancer research. Fellows engage with colleagues, lawmakers, and the public to discuss important issues and catalyze progress against cancer.

- At a ceremony on the evening before the Annual Meeting, the 2015 class of Fellows of

the AACR Academy were formally inducted.

- On June 17, several Fellows of the AACR Academy joined AACR leaders, congressional representatives, and the White House Office of Science and Technology Policy to host a special briefing titled "Saving Lives in the New Era of Precision Medicine." The participants discussed the dynamic potential of precision medicine and called upon Congress to provide robust and sustained increases in funding to the National Institutes of Health and the National Cancer Institute.



Class of 2015	
	KENNETH C. ANDERSON, MD, FAACR Dana-Farber Cancer Institute Boston, Massachusetts
	CARLOS L. ARTEAGA, MD, FAACR Vanderbilt-Ingram Cancer Center Vanderbilt University Nashville, Tennessee
	ANTON J.M. BERNs, PHD, FAACR Netherlands Cancer Institute Amsterdam, Netherlands
	BRUCE A. CHABNER, MD, FAACR Massachusetts General Hospital Boston, Massachusetts
	RONALD A. DEPINHO, MD, FAACR The University of Texas MD Anderson Cancer Center Houston, Texas
	SUSAN D. DESMOND-HELLMANN, MD, MPH, FAACR Bill and Melinda Gates Foundation Seattle, Washington
	ROBERT N. EISENMAN, PHD, FAACR Fred Hutchinson Cancer Research Center Seattle, Washington
	DOUGLAS R. LOWY, MD, FAACR National Cancer Institute Bethesda, Maryland
	CAROL L. PRIVES, PHD, FAACR Columbia University New York, New York
	STEVEN A. ROSENBERG, MD, PHD, FAACR National Cancer Institute Bethesda, Maryland
	CRAIG B. THOMPSON, MD, FAACR Memorial Sloan Kettering Cancer Center New York, New York

SCIENTIFIC ACHIEVEMENT AWARDS CELEBRATING EXCELLENCE IN CANCER SCIENCE

Brilliant scientists dedicate their careers to making the discoveries that enable them to understand, prevent, treat, and cure cancer. Through Scientific Achievement Awards and Lectureships, the AACR fosters innovation and honors exceptional investigators for their contributions.

For example, the AACR Team Science Award was created to recognize the importance of interdisciplinary collaboration to capitalize on the unparalleled opportunities made possible by the sequencing of the human genome, progress in systems biology, and the emergence of computational technologies. In addition to honoring scientific achievement, the AACR also recognizes the importance of champions of cancer research. The AACR Margaret Foti Award celebrates these individuals, whose leadership and sustained commitment to the prevention and cure of cancer have made a major impact on the field.



2015 Scientific Achievement Award Recipients



Left to right:

AACR G.H.A. Clowes Memorial Award
OWEN N. WITTE, MD
University of California, Los Angeles, California



AACR Richard and Hinda Rosenthal Memorial Award
WILLIAM C. HAHN, MD, PHD
Dana-Farber Cancer Institute, Boston, Massachusetts



AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
DONALD S. COFFEY, PHD
Johns Hopkins University School of Medicine, Baltimore, Maryland



AACR Award for Outstanding Achievement in Chemistry in Cancer Research
PHILIP S. LOW, PHD
Purdue University, West Lafayette, Indiana



AACR Award for Outstanding Achievement in Cancer Research
CHRISTOPHER R. VAKOC, MD, PHD
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York




AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
MITCHELL H. GAIL, MD, PHD
National Cancer Institute, Bethesda, Maryland



AACR Princess Takamatsu Memorial Lectureship
LEWIS C. CANTLEY, PHD, FAACR
Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, New York, New York



AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
ELIZABETH M. JAFFEE, MD
Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland



Pezcoller Foundation-AACR International Award for Cancer Research
JAMES P. ALLISON, PHD, FAACR
University of Texas MD Anderson Cancer Center, Houston, Texas



AACR Team Science Award
AR INHIBITOR TEAM:
CHARLES L. SAWYERS, MD, FAACR
Memorial Sloan Kettering Cancer Center, New York, New York



MICHAEL E. JUNG, PHD
University of California, Los Angeles, Los Angeles, California

HOWARD I. SCHER, MD
Memorial Sloan Kettering Cancer Center, New York, New York



AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship
SARA A. COURTNEIDGE, PHD
Oregon Health and Science University, Portland, Oregon



AACR-Irving Weinstein Foundation Distinguished Lecture
DAVID BALTIMORE, PHD
California Institute of Technology, Pasadena, California



AACR Distinguished Lectureship in Breast Cancer Research
ANNE-LISE BØRRERSON-DALE, DSC
University of Oslo, Oslo, Norway



AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen™
MOHAMED BENTIRES-ALJ, PHARMPHD
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland




AACR Award for Lifetime Achievement in Cancer Research
MARIO R. CAPECCHI, PHD, FAACR
University of Utah, Salt Lake City, Utah



AACR-Minorities in Cancer Research Jane Cooke Wright Memorial Lectureship
LUCILE L. ADAMS-CAMPBELL, PHD
Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.



AACR Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen™
ELECTRA D. PASKETT, PHD
Ohio State University, Columbus, Ohio



AACR-CRI Lloyd J. Old Award in Cancer Immunology
CARL H. JUNE, MD
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

SCIENTIFIC PUBLISHING

Starting with the world's first English-language cancer journal in 1916, AACR journals have provided a publication forum for discoveries that span the breadth of basic, translational, clinical, and epidemiological cancer research. The journals' editorial boards draw on experts in all disciplines, making AACR publications a trusted resource for the latest advances and providing a strong signal of quality amid the noise of a crowded scientific information landscape.

SCIENTIFIC PUBLISHING DISSEMINATING HIGH-QUALITY CANCER SCIENCE SINCE 1916

High Standards, High Impact

An indicator of journal quality is the Impact Factor, which uses article citations to measure the relative importance of a journal within its field:

- The eight AACR journals ranked in the top 30 percent in the oncology category—led by *Cancer Discovery*, *Cancer Research*, and *Clinical Cancer Research*, which rank in the top 6 percent.
- With an Impact Factor of 19.453, *Cancer Discovery* ranked fifth out of 211 oncology journals.
- *Cancer Research* continued to be the most frequently cited cancer journal in the world. *Clinical Cancer Research* ranked third among all oncology journals for number of citations.

Major Milestones in a Proud Publishing Tradition

In 2016 *Cancer Research*, the longest-running AACR journal, will celebrate its 75th anniversary. In addition, the number of articles published in the journal surpassed 50,000 in 2015.

Clinical Cancer Research marked its 20th year of publication in 2015. Since its launch in 1995, the journal has provided a vital publication outlet for high-impact translational and clinical research, helping to transform molecular and cellular insights into clinical interventions to benefit patients.

Cancer Prevention Research supported the emerging field of cancer immunoprevention in 2015, commissioning a series of invited articles on the subject and expanding its scope to accommodate an increasing number of proffered articles.

New Editorial Leadership

In September 2015, the AACR appointed Robert D. Schreiber, PhD, and Philip D. Greenberg, MD, as the new editors-in-chief of *Cancer Immunology Research*. Launched in 2013 under the leadership of Founding Editor Glenn Dranoff, MD, the journal disseminates advances in cancer immunology and immunotherapies that span the spectrum of science and medicine.

Top Oncology Journals*

1. *CA: A Cancer Journal for Clinicians*
2. *Nature Reviews Cancer*
3. *Lancet Oncology*
4. *Cancer Cell*
5. ***Cancer Discovery***
6. *Journal of Clinical Oncology*
7. *Nature Reviews Clinical Oncology*
8. *Journal of the National Cancer Institute*
9. *Leukemia*
10. *Seminars in Cancer Biology*
11. ***Cancer Research***
12. ***Clinical Cancer Research***

*Top 12 journals (by Impact Factor) out of 211; *Journal Citation Reports*®, Thomson Reuters 2015.

Defining the Frontiers of Cancer Science

Since its launch in 2001, *Molecular Cancer Therapeutics* has been a source of cutting-edge research in the area of small-molecule therapeutics. The journal recently identified large-molecule therapeutics as an emerging area in the field, and the new category has attracted a growing number of high-quality research articles.


Molecular Cancer Research curated special collections of significant journal content in 2015, highlighting critical areas such as the Ras pathway, chromatin regulation, and cell cycle and senescence.

Capturing the Interest of the Public Worldwide

As a forum for research on cancer etiology, prevention, and survivorship, *Cancer Epidemiology, Biomarkers & Prevention (CEBP)* continues to receive significant media attention. In 2015, the AACR issued 20 news releases featuring articles published in *CEBP*, generating approximately 3,200 media clips from major national and international media outlets, local news outlets, and cancer and medical trade publications.

SCIENTIFIC PUBLISHING EDITORS-IN-CHIEF

The editor-in-chief of an AACR journal establishes the publication's scientific vision, appoints an editorial board to support that vision, and maintains the journal's ethical integrity. The AACR thanks the following editors-in-chief for their hard work and stewardship of its scientific publishing program.



LEWIS C. CANTLEY, PHD, FAACR
Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College
New York, New York




JOSÉ BASELGA, MD, PHD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York



TIMOTHY R. REBBECK, PHD
Dana-Farber Cancer Institute
Boston, Massachusetts



ROBERT D. SCHREIBER, PHD
Washington University School of Medicine
St. Louis, Missouri



PHILIP D. GREENBERG, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington



SCOTT M. LIPPMAN, MD
UC San Diego Moores Cancer Center
San Diego, California




GEORGE C. PRENDERGAST, PHD
Lankenau Institute for Medical Research
Wynnewood, Pennsylvania



KENNETH C. ANDERSON, MD, FAACR
Dana-Farber Cancer Institute
Boston, Massachusetts



KAREN E. KNUDSEN, PHD
Kimmel Cancer Center
Philadelphia, Pennsylvania



NAPOLEONE FERRARA, MD, FAACR
UC San Diego Moores Cancer Center
San Diego, California



Timothy R. Rebbeck, PhD, editor-in-chief of the AACR journal Cancer Epidemiology, Biomarkers & Prevention (CEBP). Launched in 1991, CEBP was the first journal to combine these distinct disciplines in a comprehensive approach to cancer prevention.

SCIENCE AND EDUCATION

Members of the QuadW-AACR Sarcoma Expert Panel, which met in September 2015 to discuss the future of sarcoma research and improved patient outcomes.



MEETINGS AND WORKSHOPS

FORGING CONNECTIONS, BUILDING COMMUNITY, AND ADVANCING SCIENCE






AACR meetings provide a dynamic, open environment to communicate the latest advances in cancer science and medicine. The AACR convened 33 meetings in 2015, the most in its history. The meetings are crafted to meet the varied needs of the research community, and they range from small conferences on specific disease sites and emerging scientific areas to larger gatherings on topics of general interest such as molecular targets, basic science, and cancer health disparities.

The AACR also hosts educational workshops and special courses focused on the vital mission of developing the next generation of investigators. Workshops train early-career scientists in clinical trial design, molecular biology, molecular epidemiology, and related fields. World-renowned experts on the faculty supplement educational programs with mentoring, networking, and career development opportunities—transforming a class of promising scientists into a network of future collaborators.

In addition to scientific excellence, the defining characteristic of AACR meetings is collaboration—across disciplines, across institutions, and across national borders. Seven conferences on the AACR calendar were held outside the United States, and nine conferences were organized in partnership with one or more scientific organizations. By fostering these collaborative relationships, AACR meetings and workshops provide a forum for cutting-edge science while creating a community that will maximize its impact.



Laurence Zitvogel, MD, PhD, delivers a keynote lecture on “The impact of gut microbiota in cancer development and therapeutics” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in November 2015.



2015 Meetings and Workshops

MEETING HELD OUTSIDE U.S.

● WORKSHOP

● INTERNATIONAL CONFERENCE

MYC: FROM BIOLOGY TO THERAPY

January 7-10; La Jolla, California

Co-chairpersons: Dean W. Felsher, MD, PhD, Martin Eilers, PhD, Carla Grandori, DPhil, PhD, and James E. Bradner, MD

TRANSLATION OF THE CANCER GENOME COMPUTATIONAL AND SYSTEMS BIOLOGY OF CANCER

February 7-11; San Francisco, California

Co-chairpersons: William C. Hahn, MD, PhD, Lynda Chin, MD, William R. Sellers, MD, Andrea Califano, PhD, Peter K. Jackson, PhD, and Brenda J. Andrews, PhD

AACR-SNMMI JOINT CONFERENCE

February 11-14; San Diego, California

Co-chairpersons: Carolyn J. Anderson, PhD, David R. Piwnica-Worms, MD, PhD, and Christopher H. Contag, PhD

TUMOR ANGIOGENESIS AND VASCULAR NORMALIZATION: BENCH TO BEDSIDE TO BIOMARKERS

March 5-8; Orlando, Florida

Co-chairpersons: Rakesh K. Jain, PhD, Harold F. Dvorak, MD, Napoleone Ferrara, MD, FAACR, Peter Carmeliet, MD, PhD, and Helen X. Chen, MD

● WORKSHOP: ACCELERATING ANTICANCER AGENT DEVELOPMENT AND VALIDATION

May 6-8; Bethesda, Maryland

Chairperson: H. Kim Lyerly, MD

ADVANCES IN BRAIN CANCER RESEARCH

May 27-30; Washington, D.C.

Co-chairpersons: Eric C. Holland, MD, Franziska Michor, PhD, Martine F. Roussel, PhD, and Michael D. Taylor, MD, PhD

METABOLISM AND CANCER

June 7-10; Bellevue, Washington

Co-chairpersons: Ralph J. DeBerardinis, MD, PhD, David M. Sabatini, MD, PhD, Almut Schulze, PhD

● WORKSHOP: METHODS IN CANCER BIOSTATISTICS—CLINICAL TRIAL DESIGNS FOR TARGETED AGENTS

June 7-13; Lake Tahoe, California

Chairperson: Steven Piantadosi, MD, PhD

PRECISION MEDICINE SERIES: INTEGRATING CLINICAL GENOMICS AND CANCER THERAPY

June 13-16; Salt Lake City, Utah

Co-chairpersons: Charles L. Sawyers, MD, FAACR, Elaine R. Mardis, PhD, and Arul M. Chinnaiyan, MD, PhD

13TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

June 17-20; Lugano, Switzerland

Co-chairpersons: Franco Cavalli, MD, and Michele Ghilmini, MD, PhD

AACR-SIC-EACR JOINT CONFERENCE: ANTICANCER DRUG ACTION AND DRUG RESISTANCE—FROM BIOLOGY TO THE CLINIC

June 20-23; Florence, Italy

Co-chairpersons: Richard M. Marais, PhD, Pasi A. Jänne, MD, PhD, and Riccardo Dolcetti, MD

● WORKSHOP: METHODS IN CLINICAL CANCER RESEARCH (EUROPE)

June 20-26; Flims, Switzerland

Co-directors: Stefan Sleijfer, MD, PhD

(ECCO), Stephen M. Hahn, MD (AACR), Corneel Coens, MSc (EORTC), and Christian Ditttrich, MD (ESMO)

● WORKSHOP: MOLECULAR BIOLOGY IN CLINICAL ONCOLOGY

July 19-26; Snowmass, Colorado

Director: Levi A. Garraway, MD, PhD
Co-directors: Charles L. Sawyers, MD, FAACR, Mark W. Geraci, MD, and Jean Y. Tang, MD, PhD

● WORKSHOP: ASCO/AACR METHODS IN CLINICAL CANCER RESEARCH

July 25-31; Vail, Colorado

Co-directors: S. Gail Eckhardt, MD, Neal J. Meropol, MD, and Yu Shyr, PhD

● WORKSHOP: INTEGRATIVE MOLECULAR EPIDEMIOLOGY

August 10-14; Boston, Massachusetts

Director: Thomas A. Sellers, PhD, MPH
Co-directors: Ellen L. Goode, PhD, and Peter Kraft, PhD

● WORKSHOP: CROUCHER SUMMER COURSE IN CANCER BIOLOGY

August 10-14; Hong Kong

Co-directors: Irene O. L. Ng, MD, PhD, Tak W. Mak, PhD, FAACR, Wendy Hsiao, PhD

● CRI-CIMT-EATI-AAACR: THE INAUGURAL INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE—TRANSLATING SCIENCE INTO SURVIVAL

September 16-19; New York, New York

Scientific Planning Committee: James P. Allison, PhD, FAACR, Cedrik M. Britten, MD, Glenn Dranoff, MD, Alexander M.M. Eggermont, MD, PhD, Carl G. Figdor, PhD, Wolf Hervé Fridman, MD, PhD, Philip D. Greenberg, MD, Axel Hoos, MD, PhD, Elizabeth M. Jaffee, MD, Peter W.M. Johnson, MD, Guido Kroemer, MD, PhD,

Nils Lonberg, PhD, Cornelis J.M. Melief, PhD, Ellen Puré, PhD, and Robert D. Schreiber, PhD

The AACR collaborated with the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), and the European Academy of Tumor Immunology (EATI) to launch this groundbreaking conference. More than 1,400 attendees gathered in New York for a sold-out event that brought together leading experts in immunotherapy to discuss the latest developments in the field. Interest in the conference was so high that the collaborating organizations are working to make it an annual event.

CHROMATIN AND EPIGENETICS IN CANCER

September 24-27; Atlanta, Georgia

Co-chairpersons: Peter A. Jones, DSc, PhD, FAACR, Sharon Y.R. Dent, PhD, and Charles M. Roberts, MD, PhD

ADVANCES IN BREAST CANCER RESEARCH

October 17-20; Bellevue, Washington

Co-chairpersons: Matthew J. Ellis, MD, PhD, Charles M. Perou, PhD, and Jane E. Visvader, PhD

ADVANCES IN OVARIAN CANCER RESEARCH

October 17-20; Orlando, Florida

Co-chairpersons: Kathy R. Cho, MD, Benjamin G. Neel, MD, PhD, and Douglas A. Levine, MD

● FRONTIERS IN BASIC CANCER RESEARCH

October 23-26; Philadelphia, Pennsylvania

Co-Chairpersons: James P. Allison, PhD, FAACR, John E. Dick, PhD, Victor E. Velculescu, MD, PhD, and Nathanael S. Gray, PhD

The chairpersons for the latest edition of this biennial conference convened three lectures around the theme “Converging Topics and Emerging Research.” These lectures identified the areas of greatest activity in basic research in the past year — “Immunology, Tumor Microenvironment, and Inflammation”; “Cell of Origin, Stem Cells, and Genetics”; and “Genetics and New Technologies in Cancer Research” — and illustrated how collaboration across these disciplines can power progress against cancer.

BASIC SCIENCE OF SARCOMAS

November 3-4; Salt Lake City, Utah

[Complementary program to the Connective Tissue Oncology Society Annual Meeting]
Co-chairpersons: Robert G. Maki, MD, PhD, Lee J. Helman, MD, Brian A. Van Tine, MD, PhD, Jonathan A. Fletcher, MD, and Angelo Paolo Dei Tos, MD

● AACR-NCI-EORTC MOLECULAR TARGETS AND CANCER THERAPEUTICS

November 5-9; Boston, Massachusetts

Scientific Committee Co-chairpersons: Levi A. Garraway, MD, PhD, Lee J. Helman, MD, and Jean-Charles Soria, MD, PhD

Held biennially in the United States, this conference developed from the original EORTC-NCI meetings on drug discovery and development which began in 1988. The AACR joined the partnership in 1999 in response to the need for more frequent meetings to keep pace with the rapid advancement of molecular biology and genetics, and the consequent emergence of many new targets for cancer therapeutics. In 2015, the U.S. edition offered attendees the opportunity to submit late-breaking abstracts for the first

time. A total of 86 late-breaking abstracts were received for consideration as proffered presentations.

● WORKSHOP: TRANSLATIONAL CANCER RESEARCH FOR BASIC SCIENTISTS

November 8-13; Boston, Massachusetts

Co-chairpersons: Tom Curran, PhD, FAACR, George D. Demetri, MD, and Pasi A. Jänne, MD, PhD

ADVANCES IN PEDIATRIC CANCER RESEARCH: FROM MECHANISMS AND MODELS TO TREATMENT AND SURVIVORSHIP

November 9-12; Fort Lauderdale, Florida

Co-chairpersons: Scott A. Armstrong, MD, PhD, Charles G. Mullighan, MBBS, MD, Kevin M. Shannon, MD, and Kimberly Stegmaier, MD

● NEW HORIZONS IN CANCER RESEARCH CONFERENCE

November 12-15; Shanghai, China

Co-chairpersons: Lewis C. Cantley, PhD, FAACR, and Carlos L. Arteaga, MD, FAACR

Following its successful launch in 2014, the second edition of this annual conference brought the most exciting discoveries from the AACR Annual Meeting 2015 to a receptive audience in China. The program was enhanced with presentations from outstanding international speakers and local experts. The centerpiece of the AACR’s international outreach efforts, the New Horizons conference has created a foundation for global collaborations.

● EIGHTH ANNUAL AACR CONFERENCE ON THE SCIENCE OF CANCER HEALTH DISPARITIES IN RACIAL/ETHNIC MINORITIES AND THE MEDICALLY UNDERSERVED

November 13-16; Atlanta, Georgia

Co-chairpersons: John M. Carethers, MD, Marcia R. Cruz-Correa, MD, PhD, Mary Jackson Scroggins, MA, Edith A. Perez, MD, Beti Thompson, PhD, and Cheryl L. Willman, MD

Tracing its origins to a 2006 think tank sponsored by the AACR and the NCI Center to Reduce Cancer Health Disparities, this conference is the only one to address the full scientific spectrum of disparities, including basic science, clinical research, population science, behavioral research, and cancer survivorship. The 2015 conference brought together physicians, scientists, health professionals, and health care leaders working in a variety of fields to foster interdisciplinary collaborations.

The keynote address for the conference was delivered by Douglas R. Lowy, MD, Acting Director of the National Cancer Institute. Dr. Lowy, who has made reducing cancer health disparities a primary focus of the NCI, discussed “Understanding and overcoming cancer disparities in the U.S. and abroad.”

THE 11TH ANNUAL PERSONALIZED MEDICINE CONFERENCE

November 18-19; Boston, Massachusetts

Co-chairpersons: Raju Kucherlapati, PhD, and Scott Weiss, MD, MS

DEVELOPMENTAL BIOLOGY AND CANCER

November 30-December 3; Boston, Massachusetts

Co-chairpersons: Hans Clevers, MD, PhD, FAACR, Stuart H. Orkin, MD, PhD, and Suzanne J. Baker, PhD

TUMOR METASTASIS

November 30-December 3; Austin, Texas

Co-chairpersons: Bruce R. Zetter, PhD, Melody A. Swartz, PhD, and Jeffrey W. Pollard, PhD

CSHA-AAACR JOINT CONFERENCE: BIG DATA, COMPUTATION AND SYSTEMS BIOLOGY IN CANCER

December 2-5; Suzhou, China

Organizers: Andrea Califano, PhD, William C. Hahn, MD, PhD, Satoru Miyano, PhD, and Xuegong Zhang, PhD

NONCODING RNAs AND CANCER

December 4-7; Boston, Massachusetts

Co-chairpersons: Joshua Mendell, MD, PhD, Jeannie T. Lee, PhD, and Howard Y. Chang, MD, PhD

● CTRC-AAACR SAN ANTONIO BREAST CANCER SYMPOSIUM

December 8-12; San Antonio, Texas

Co-directors: Carlos L. Arteaga, MD, FAACR, Virginia G. Kaklamani, MD, C. Kent Osborne, MD

The 38th annual San Antonio Breast Cancer Symposium also marked the ninth year of the AACR’s collaboration with the Cancer Therapy and Research Center at UT Health Science Center San Antonio and Baylor College of Medicine. The 2015 program presented essential cutting-edge science combined with engrossing discussion for basic, translational, and clinical cancer research professionals.

THINK TANKS

AACR MEMBERS DRIVING INNOVATION

The most respected minds in the cancer research community convene to identify and nurture emerging scientific areas through AACR Think Tanks. These forums support and encourage open dialogue, shaping the next wave of innovations in cancer science. The action-oriented conversations continue well beyond the conference table, sparking collaborations that catalyze change.

Inaugural AACR Radiation Oncology Think Tank: Optimizing Cancer Care Through Advancements in Radiation Science and Medicine

January 11-13; Fort Myers, Florida
Chairperson: Theodore S. Lawrence, MD, PhD

Goal: To provide a forum for radiation specialists, trainees, and distinguished investigators in other oncology fields to focus on radiation science and medicine, exploring its challenges and opportunities across all specialties.

QuadW-AACR Sarcoma Expert Panel: Envisioning the Future of Sarcoma Research and Improved Patient Outcomes

September 11-12; Moran, Wyoming
Chairperson: Lee J. Helman, MD

Goal: To convene a diverse group of sarcoma experts to identify and evaluate the most promising areas in the field and to encourage and support young investigators and their research efforts.



Members of the inaugural AACR Radiation Oncology Think Tank, which met in January 2015 to discuss optimizing cancer care through advancements in radiation science and medicine.


SCIENCE EDUCATION AND CONTINUING MEDICAL EDUCATION DEVELOPING CURRENT AND FUTURE CANCER RESEARCH INNOVATORS

The AACR sustains the pipeline of diverse, talented, and engaged cancer researchers through science education programs which nurture students from high school all the way to their first independent position. As physician-scientists and clinicians progress in their careers, the AACR continues their training through its Continuing Medical Education (CME) program. As a fully accredited ACCME CME provider since 2010, the AACR enables clinical investigators to apply critical aspects of basic cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.



AACR-Thomas J. Bardos Science Education Scholar Awards for Undergraduate Students

Twenty-one remarkable undergraduate students attended the AACR Annual Meeting 2015 as Bardos awardees. The program offers students an invaluable opportunity to learn about the latest developments in cancer research, interact with prominent researchers, and form lasting connections with other gifted young scientists.



Undergraduate Student Caucus and Poster Competition

Undergraduate students learn about careers in cancer research from leaders in the field, who present their groundbreaking research, discuss educational pathways, and offer career development advice at the Annual Meeting. Students also present their own research, receiving feedback from peers as well as from experts. The program marked its 10-year anniversary in 2015, celebrating nearly 700 undergraduate participants since 2006.



Special Program for High School Students

Even the youngest scientists can learn about cancer research directly from experts while presenting their own novel research. In 2015, 350 students from local schools as well as students working in laboratories of AACR members participated in the program. Students at the Annual Meeting heard from guest speakers Devon Still — a former NFL player whose daughter is a neuroblastoma survivor — and Reggie Love, a writer, editor, and former special assistant and personal aide to President Obama.


Continuing Medical Education

The AACR provides physician-scientists and clinicians with a wide range of opportunities to maintain their competence and incorporate new knowledge into their practice. CME credit was offered at 22 different AACR meetings in 2015, including 15 special conferences, three joint conferences, three workshops, and the Annual Meeting. AACR journals provided another educational resource, offering credit to investigators for reading articles as well as for reviewing manuscripts. A total of 3,234 researchers and clinicians claimed CME credit from the AACR in 2015, ensuring that caregivers apply the full spectrum of basic, translational, and clinical cancer science to improving the lives of their patients.


SCIENTIFIC REVIEW AND GRANTS ADMINISTRATION ADVANCING CANCER SCIENCE THROUGH VITAL FUNDING

The next great advances in cancer research will be achieved only if scientists receive essential research funding. The cancer community has entrusted the AACR with the stewardship of such grant funding for over two decades. Since 1993, the AACR has administered nearly \$300 million in research support, providing scientific oversight as well as expert peer review and grants administration that is fast, flexible, rigorous, and transparent.

GRANT MECHANISMS
(% Total Grants Disbursed)



ORGAN/DISEASE TYPE
(% Total Grants Disbursed)



\$60 million

Was awarded in 2015 to fund the research of six new “Dream Teams” through the AACR’s partnership with SU2C.

54

Scientists received essential research funding in 2015 through 44 additional grants totaling \$8 million.

\$6.75 million

Will be awarded over the next five years through the NextGen Grants for Transformative Cancer Research Program. This exciting new program, initiated by AACR Past President Carlos L. Arteaga, MD, FAACR, will provide early-career investigators with the resources they need to conduct creative, paradigm-shifting cancer research that will catalyze major breakthroughs in the field.

\$460,000

Was awarded to nine postdoctoral fellows for basic cancer research through an unprecedented expansion of the Basic Cancer Research Fellowship Program. The AACR emphasizes the critical importance of basic research as the foundation of future translational and clinical breakthroughs for cancer patients.



The AACR and Stand Up To Cancer recognize the leaders of the OCReA-NOCC Ovarian Cancer Dream Team at the AACR Annual Meeting 2015. Left to right: Laura K. Shawver, PhD, SU2C Scientific Advisory Committee Member; Kathleen A. Gavin, Ovarian Cancer Dream Team Advocate; Brittany Daniel, SU2C celebrity ambassador; Alan D. D’Andrea, MD, Ovarian Cancer Dream Team Leader; Elizabeth M. Swisher, MD, Ovarian Cancer Dream Team Co-leader; and Margaret Foti, PhD, MD (hc), AACR chief executive officer.



Laurent Fattet, PhD (right), from the University of California, San Diego, is congratulated by AACR President (2014-2015) Carlos L. Arteaga, MD, FAACR (left), on receiving a 2015 AACR Basic Cancer Research Fellowship.



THE AACR AND STAND UP TO CANCER: ACCELERATING PROGRESS

Fostering innovative and collaborative cancer science requires innovative and collaborative funding mechanisms. The AACR is proud to serve as the Scientific Partner of Stand Up To Cancer (SU2C), a groundbreaking movement to accelerate the pace of translational cancer research, get new therapies to patients quickly, and save lives.



Left to right: William G. Nelson, MD, PhD, SU2C Scientific Advisory Committee Vice Chairperson; cancer survivor Pearce Quesenberry; SU2C Co-founder Katie Couric; and AACR CEO Margaret Foti, PhD, MD (hc), participate in a Parade magazine Facebook chat before the SU2C telecast.

Opposite page: Phillip A. Sharp, PhD (top left), SU2C Scientific Advisory Committee Chairperson; Arnold J. Levine, PhD (top right), SU2C Scientific Advisory Committee Vice Chairperson.

As a program of the Entertainment Industry Foundation, SU2C focuses the industry's resources to increase awareness of the urgent need for cancer research and raise needed funds. The AACR works with SU2C's blue-ribbon Scientific Advisory Committee (SAC) to conduct rigorous, competitive peer review, identifying the most promising research projects to fund and providing expert scientific oversight for those projects. The committee is composed of highly accomplished clinical researchers, senior laboratory researchers, and physician-scientists from the AACR membership as well as patient advocates experienced in grant review and clinical trials. The chairperson of the committee is Nobel Laureate Phillip A. Sharp, PhD, FAACR, and Arnold J. Levine, PhD, FAACR, and William G. Nelson, MD, PhD, serve as vice chairpersons.

Since SU2C's inception in 2008, the AACR has worked with SU2C to launch and administer 19 Dream Teams and two Translational Research Teams of top researchers addressing specific problems in cancer, as well as 26 Innovative Research Grants to individual, early-career investigators to support high-risk projects that also have a high level of potential impact on the prevention or treatment of cancer. As part of its

oversight, the AACR organizes an annual SU2C Scientific Summit at which Dream Teams and Innovative Research Grant recipients report on their progress and brainstorm opportunities for new collaborations and accelerated research.

In addition to fostering collaboration among scientists, SU2C fosters collaboration among funders, working with leading cancer organizations worldwide to co-sponsor high-impact research. For example, in 2015 SU2C and the AACR launched Dream Teams focused on ovarian cancer, with the Ovarian Cancer Research Fund Alliance and National Ovarian Cancer Coalition; on lung cancer, with the American Cancer Society; on colorectal cancer, with the Dutch Cancer Society; on pancreatic cancer, with Cancer Research UK and The Lustgarten Foundation; on cancer stem cells in brain cancers, with Genome Canada, Canadian Institutes of Health Research, and Ontario Institute for Cancer Research; and on breast cancer, with the Canadian Breast Cancer Foundation with support from CIBC, and the Ontario Institute for Cancer Research. With the support of these organizations, SU2C and the AACR are breaking down barriers to progress and building the teams that will solve the cancer problem.



SU2C Scientific Advisory Committee

- Phillip A. Sharp, PhD, FAACR
- Arnold J. Levine, PhD, FAACR
- William G. Nelson, MD, PhD
- Julian Adams, PhD
- Frederick R. Appelbaum, MD
- Elizabeth H. Blackburn, PhD, FAACR
- Richard B. Gaynor, MD
- William N. Hait, MD, PhD, FAACR
- Lee J. Helman, MD
- Waun Ki Hong, MD, FAACR
- William G. Kaelin Jr., MD, FAACR
- Michael B. Kastan, MD, PhD
- Richard D. Kolodner, PhD, FAACR
- Guillermina Lozano, PhD
- Tak W. Mak, PhD, FAACR
- Cecil B. Pickett, PhD
- Laura K. Shawver, PhD
- Ellen V. Sigal, PhD
- David A. Tuveson, MD, PhD

SU2C Funding Partners

- Melanoma Research Alliance
- Prostate Cancer Foundation
- Cancer Research Institute
- St. Baldrick's Foundation
- Dutch Cancer Society KWF
- Cancer Research UK
- Lustgarten Foundation
- Farrah Fawcett Foundation
- American Cancer Society
- Ovarian Cancer Research Fund Alliance
- National Ovarian Cancer Coalition
- Canadian Breast Cancer Foundation
- Genome Canada
- Canadian Institute of Health Research
- Ontario Institute for Cancer Research
- Van Andel Research Institute

POLICY AND ADVOCACY

AACR CEO Margaret Foti, PhD, MD (hc), welcomes scientists, advocates, and government officials to the Reception to Celebrate Medical Research, September 16, 2015. Held in the Senate Office Building in Washington, the reception was a highlight of the Rally for Medical Research Hill Day.

From research funding to the regulation of new treatments, the success of the cancer research enterprise is closely tied to decisions made by government agencies. Through its Office of Science Policy and Government Affairs, the AACR connects researchers, clinicians, survivors, and advocates with lawmakers and regulators, maintaining a dialogue between stakeholders and ensuring that public interest is aligned with patient interest.

SCIENCE POLICY AND GOVERNMENT AFFAIRS CONNECTING RESEARCHERS AND ADVOCATES WITH LEGISLATORS

Rally for Medical Research Hill Day

As the founding organizer of the original Rally for Medical Research — held on the streets of Washington during the 2013 Annual Meeting — the AACR forged a coalition of more than 200 organizations and institutions to call for increased federal investment in biomedical research. On September 17, that coalition moved from the streets to Capitol Hill, as more than 300 organizations came together for the Rally for Medical Research Hill Day. The AACR and its partners held more than 200 meetings with members of Congress to advocate for robust, sustained, and predictable increases in funding for the National Institutes of Health (NIH) in 2016 and beyond. This collaborative effort was rewarded in December, when Congress approved an omnibus spending bill that contained a \$2 billion increase for the NIH — the first meaningful budgetary increase for the agency in more than a decade.

Congressional Briefings

Education is a critical component of advocacy. The AACR brings leading scientists and clinicians to Capitol Hill to provide members of Congress with the scientific background they need to make informed decisions.

• **Electronic Cigarettes.** On May 14, Roy S. Herbst, MD, PhD, chair of the AACR Tobacco and Cancer Subcommittee, presented the latest research on electronic nicotine delivery systems (ENDS) and suggested steps lawmakers can take to limit the marketing of these products to young people.

• **Diagnostics and Precision Medicine.** On June 8, the AACR partnered with AdvaMedDx (an international group of leading manufacturers of in vivo diagnostics) to brief Congress on the leading role played by diagnostics in precision medicine.

• **Saving Lives in the New Era of Precision Medicine.** On June 17, AACR members Carlos Arteaga, MD, FAACR, José Baselga, MD, PhD, FAACR, Elizabeth Blackburn, PhD, FAACR, Joan Brugge, PhD, FAACR, and Eric Rubin, MD, partnered with the White House Office of Science and Technology Policy to highlight the promise of precision medicine and the need for sustained funding to realize that promise.

Public Workshops

Because of its strong relationships with academia, industry, and government, the AACR is uniquely positioned to bring the cancer community together to overcome obstacles to improved patient care.

• **Companion Diagnostics.** On March 24, the AACR worked with the U.S. Food and Drug Administration (FDA) and the American Society of Clinical Oncology to host a workshop to identify and address the challenges related to harmonizing companion diagnostics across a class of targeted therapies. Bringing together patients, regulators, clinicians, drug developers, and diagnostic manufacturers, the workshop emphasized the need for comparability between diagnostics across a class of drugs. Laura van 't Veer, PhD, Chairperson of the AACR Diagnostics Policy Subcommittee, served as Co-chairperson of the workshop and moderated a panel discussion on comparing diagnostic tests.

• **Dose-Finding of Small-Molecule Oncology Drugs.** On May 18 and 19, the AACR partnered with the FDA to host a workshop focused on replacing the conventional dose-escalation clinical trial design with an innovative design that bases dose-selection decisions on clinical, pharmacologic, and pharmacometric data. Workshop Co-chairpersons included AACR Regulatory Science and Policy Subcommittee members Eric Rubin, MD, and Pasi Jänne, MD, PhD.



SURVIVOR AND PATIENT ADVOCACY EMPOWERING AND INSPIRING PATIENTS AND ADVOCATES

Patients are at the heart of the AACR's mission to prevent and cure cancer and they are also vital partners in achieving that mission. Through the Survivor and Patient Advocacy Program, the AACR empowers patients, caregivers, and patient advocates to take action on several fronts: funding to sustain scientific inquiry, participation in clinical trials to accelerate discovery, and finding resources for the challenging journey through diagnosis to treatment to survivorship.

Scientist↔Survivor Program

Participants partner with scientist mentors and attend scientific sessions at AACR meetings, forging a dialogue that increases understanding in both directions. Mentors provide survivors and advocates with the scientific context for the discoveries presented, while the survivors offer the scientists a critical patient perspective that informs their future investigations.

In April, a total of 34 survivors participated in the program during the AACR Annual Meeting 2015 in

Philadelphia — including six advocates from outside the United States, the largest number of international advocates in the program's history. Another 14 survivors interacted with scientist mentors during the AACR Conference on the Science of Cancer Health Disparities in November.


Cancer Today Magazine

The AACR's magazine guides patients, survivors, and caregivers through every step of their cancer journey and empowers patients to become active partners in their own treatment. With trusted reporting on the latest advances



in cancer research and useful advice for living life as a patient or survivor, *Cancer Today* provides practical knowledge and inspires real hope.

In 2015, the magazine appointed **William G. Nelson, MD, PhD, as editor-in-chief.** Dr. Nelson is the director of the Johns Hopkins Kimmel Cancer Center in Baltimore and a noted medical oncologist and cancer researcher.



Cancer Today was also honored for its design excellence in 2015; the magazine was a finalist in the Feature Design category of *Folio* magazine's Ozzie Awards and won a Bronze EXCEL Award for Feature Story Design.



Participants in the Scientist↔Survivor Program, held during the AACR Annual Meeting 2015.

DISTINGUISHED PUBLIC SERVICE AWARDS HONORING EXTRAORDINARY CONTRIBUTIONS

During the opening ceremony of the Annual Meeting, the AACR honored outstanding men and women who have contributed substantially to the cancer community with Distinguished Public Service Awards. By building relationships in the political arena to ensure funding for cancer research; by engaging the public in understanding cancer research; by creating partnerships to streamline the regulatory process for innovative cancer therapies; and by building relationships in the international community to promote cancer control, these individuals advance the AACR's mission.



Miri Ziv, Director General of the Israel Cancer Association, accepts the 2015 AACR Award for Distinguished Public Service and Global Impact in Cancer Advocacy during the opening ceremony of the Annual Meeting.



2015 AACR Distinguished Public Service Award
THE HONORABLE ROBERT P. CASEY JR.
(D - PA)
United States Senator
Scranton, Pennsylvania



2015 AACR Distinguished Public Service Award
SIDDHARTHA MUKHERJEE, MD, PHD
Assistant Professor, Department of Medicine,
Columbia University
New York, New York



2015 AACR Award for Distinguished Public Service and
Global Impact in Cancer Advocacy
MIRI ZIV
Director General, Israel Cancer Association
Givatayim, Israel



2015 AACR Distinguished Public Service Award
RICHARD PAZDUR, MD
Director of the Office of Hematology and
Oncology Products,
U.S. Food and Drug Administration
Silver Spring, Maryland

MEMBERSHIP

The foundation of the AACR is a diverse and dedicated membership, numbering over 35,000 investigators from around the world. These members are the heart of the cancer research community, working together in the global effort to prevent and cure cancer. Participation in cutting-edge AACR programs provides members with vital opportunities to foster important relationships and collaborations across the entire spectrum — from early-career researchers to senior investigators, from academia to industry, and from scientists to patient advocates. Members of the AACR make critical discoveries in all areas of inquiry, from epidemiological, prevention, and basic science to translational and clinical research.

AACR MEMBERSHIP MEMBERS BY THE NUMBERS

Active Members:
Established laboratory researchers, physician-scientists, clinicians, and population scientists

58
Nobel Laureates have been members of the AACR.

Associate Members:
Young laboratory scientists and physicians-in-training (graduate students, medical students and residents, and clinical and postdoctoral fellows)

103
Patient advocates are members of the AACR.

Student Members:
Undergraduate and high school students

2,658
Individuals have been AACR members for more than 25 years.


Emeritus Members:
Active members who have reached the age of 70 years

143
Individuals have been AACR members for more than 50 years.


Affiliate Members:
Other health care professionals (practicing oncologists, nurses, laboratory technicians, non-scientific corporate professionals, and patient advocates)

101
Countries are represented by AACR members.


MEMBERS BY GENDER




MEMBERS BY DEGREE



MEMBERS BY CATEGORY




MEMBERS BY WORK SETTING



Note: Totals may not equal 100% due to rounding.

MEMBERS BY RACE/ETHNICITY



DIVERSIFYING THE CANCER WORKFORCE

Cancer touches everyone, affecting patients and their loved ones regardless of their age, ethnicity, or gender. To maximize patient benefit, the AACR works to ensure that the cancer workforce is as diverse as the community of patients it serves. For decades the AACR has pursued this goal by identifying, training, and mentoring talented investigators in populations that are underrepresented in the scientific community. These efforts are coordinated by three vital groups: Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), and the Associate Member Council (AMC).



AACR-Minorities in Cancer Research (2015 Council Chairperson: Edith A. Perez, MD)

- The innovative AACR-MICR Distinguished Lectureship Series brings the AACR's world-class scientific programming to the campuses of Minority Serving Institutions, to inspire young minority students and educators at these institutions to pursue a career in cancer research. The 2015 Lecture series was held on November 16 at Clark Atlanta University, Atlanta, Georgia. Organized by chairpersons John M. Carethers, MD, and

Rick A. Kittles, PhD, the lecture program was titled "Disparities in prostate cancer: Outcomes to biomarkers."

- This past year marked the 30th anniversary of the AACR Minority Scholar in Cancer Research Awards program. These awards support the education and training of minority researchers and increase the visibility and recognition of minorities in cancer research. Through a generous grant from the National Cancer Institute's Center to Reduce Cancer Health Disparities, the program has supported more than 1,000 trainees since its establishment.



Early-career scientists discuss careers in clinical and translational research with Susan M. Galbraith, MD, at a professional advancement session at the AACR Annual Meeting 2015.



AACR Women in Cancer Research (2015 Council Chairperson: Victoria M. Richon, PhD)

- The AACR Women in Cancer Research Scholar Awards enhance the education and training of women scientists while increasing their visibility. In 2015, a total of 30 young investigators attended the AACR Annual Meeting through the awards. The program was also expanded in 2015 to support attendance at Special Conferences, enabling early-career female investigators to focus in on their chosen areas of research.

- The AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship was established in honor of Charlotte Friend, PhD, renowned virologist and discoverer of the Friend virus, to recognize a scientist who has made major contributions to the field of cancer research and furthered the advancement of women in science. In 2015, the eighteenth annual lecture was delivered by **Sara A. Courtneidge, PhD**, Oregon Health and Science University, Portland, Oregon. Dr. Courtneidge delivered her award lecture, titled "Cancer cell invasion and metastasis," at the AACR Annual Meeting in Philadelphia.



AACR Associate Member Council (2015 Chairperson: Mark D. Stewart, PhD)

- In 2015, the Associate Member Council launched three new AMC-led committees. The Communications Committee enhances communication with Associate Members by providing them with information on the AACR and AMC programming, career advancement, and professional development. The Fundraising Committee increases awareness of and support for the AACR and for cancer research. The Program

Committee creates career development content and fosters new and existing networking opportunities for Associate Members.

- The AMC recognizes the importance of advocating for increased funding for early-career cancer scientists. In 2015, a representative member of the AMC attended the "Rally for Medical Research Hill Day," where the AACR joined with more than 300 organizations from across the country to advocate for robust, sustained, and predictable increases in funding for the National Institutes of Health.

LEADERSHIP AACR OFFICERS AND DIRECTORS

Officers



Left to right:

President

JOSÉ BASELGA, MD, PHD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York

President Elect

NANCY E. DAVIDSON, MD
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania



Treasurer

WILLIAM N. HAIT, MD, PHD, FAACR
Janssen Research and Development, LLC
Raritan, New Jersey

Past President

CARLOS L. ARTEAGA, MD, FAACR
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee



Chief Executive Officer

MARGARET FOTI, PHD, MD (HC)
American Association for Cancer Research
Philadelphia, Pennsylvania

Board of Directors



JAMES P. ALLISON, PHD, FAACR
University of Texas MD Anderson Cancer Center
Houston, Texas

MARY C. BECKERLE, PHD
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah




MICHAEL A. CALIGIURI, MD
Comprehensive Cancer Center, The Ohio State University
Columbus, Ohio

HANS CLEVERS, MD, PHD, FAACR
Hubrecht Institute
Utrecht, Netherlands



GEORGE D. DEMETRI, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

RONALD M. EVANS, PHD, FAACR
Salk Institute for Biological Studies
La Jolla, California



ELIZABETH M. JAFFEE, MD
Johns Hopkins University
Baltimore, Maryland

SCOTT M. LIPPMAN, MD
University of California San Diego Moores Cancer Center
La Jolla, California



PATRICIA M. LORUSSO, DO
Yale Cancer Center
New Haven, Connecticut

GUILLERMINA LOZANO, PHD
University of Texas MD Anderson Cancer Center
Houston, Texas



RICHARD M. MARAIS, PHD
Cancer Research UK Manchester Institute
Manchester, England

ELAINE R. MARDIS, PHD
The Genome Institute
Washington University School of Medicine
Saint Louis, Missouri



EDITH A. PEREZ, MD
Genentech
South San Francisco, California

M. CELESTE SIMON, PHD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania



VICTOR E. VELCULESCU, MD, PHD
Johns Hopkins Kimmel Comprehensive Cancer Center
Baltimore, Maryland

The AACR thanks its officers and members of the board of directors for their vision, their wisdom, and their tireless efforts on behalf of the cancer research community.

Outgoing AACR President (2014–2015) Carlos L. Arteaga, MD, FAACR (right), hands the gavel to incoming President José Baselga, MD, PhD, FAACR (left) at the AACR Annual Business Meeting of Members.



Members of the AACR Board of Directors for 2015-2017.

LEADERSHIP AACR FOUNDATION OFFICERS AND TRUSTEES

World-class scientists work with leaders in finance, law, healthcare, and nonprofit management to guide the fundraising and funding activities of the AACR Foundation. Their expert stewardship ensures that 88 cents of every dollar raised by the foundation goes to support lifesaving cancer science.



Mitchell R. Stoller, Executive Director of the AACR Foundation, thanks supporters of the AACR at the Partners in Progress Reception during the AACR Annual Meeting 2015.


Officers



Left to right:
Chairman and President
RAYMOND N. DUBOIS, MD, PHD, FAACR
Medical University of South Carolina
Charleston, South Carolina
Vice Chairman
WILLIAM H. MEARS JR.
Brown Brothers Harriman Trust Co. LLC
Richmond, Virginia



Secretary-Treasurer and CEO
MARGARET FOTI, PHD, MD (HC)
American Association for Cancer Research
Philadelphia, Pennsylvania
Founding Chairman of the Board and President Emeritus
BAYARD D. CLARKSON, MD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York



Executive Director of the AACR Foundation
MITCHELL R. STOLLER
American Association for Cancer Research
Philadelphia, Pennsylvania

Trustees



BEVERLY W. AISENBREY
Frederic W. Cook and Co. Inc
New York, New York
CARLOS L. ARTEAGA, MD, FAACR
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee



JOSÉ BASELGA, MD, PHD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York
ELIZABETH H. BLACKBURN, PHD, FAACR
The Salk Institute for Biological Studies
La Jolla, California



FAYE FLORENCE, ESQ.
Attorney, Non-Profit Board Member
Chestnut Hill, Massachusetts
CATHY FRASER
Tenet Healthcare Corporation
Rochester, Minnesota



JUDY E. GARBER, MD, MPH, FAACR
Dana-Farber Cancer Institute
Boston, Massachusetts
NANCE GUILMARTIN
Author, Consultant
Ipswich, Massachusetts



WILLIAM N. HAIT, MD, PHD, FAACR
Janssen Research and Development LLC
Raritan, New Jersey
WEN-JEN HWU, MD, PHD
University of Texas MD Anderson Cancer Center
Houston, Texas



TYLER JACKS, PHD, FAACR
Massachusetts Institute of Technology
Cambridge, Massachusetts
V. CRAIG JORDAN, OBE, PHD, DSC, FAACR
University of Texas MD Anderson Cancer Center
Houston, Texas



ELEANOR D. KRESS
Wilmington Trust Retirement and Institutional Services Co.
New York, New York
SHERRY LANSING
The Sherry Lansing Foundation
Los Angeles, California



JOHN E. LEONARD, PHD
Vaccinex Inc.
Carlsbad, California
LAURENCE J. MARTON, MD
University of California, San Francisco
San Francisco, California



FRANK MCCORMICK, PHD, FAACR
University of California, San Francisco
San Francisco, California
JOHN E. OXENDINE
Blackstar Management
Boca Raton, Florida



ANIL K. RUSTGI, MD
University of Pennsylvania
Philadelphia, Pennsylvania
STEPHEN D. RYAN
Morgan Stanley Wealth Management
Merrill Lynch Private Banking and Investment Group
Pittsford, New York



CHARLES L. SAWYERS, MD, FAACR
Memorial Sloan Kettering Cancer Center
New York, New York
ELLEN V. SIGAL, PHD
Friends of Cancer Research
Washington, D.C.



GEOFFREY M. WAHL, PHD, FAACR
The Salk Institute for Biological Studies
La Jolla, California

LEADERSHIP COMMITTEE CHAIRPERSONS

Some committees define the research agenda for the cancer community, while others guide the AACR's programs and initiatives in support of that agenda. The AACR is grateful to the committee chairpersons and members who volunteer their time and talent in support of its mission.

Standing Committees

CANCER PREVENTION

Co-chairpersons: Ernest T. Hawk, MD, MPH, and Scott M. Lippman, MD

CLINICAL AND TRANSLATIONAL CANCER RESEARCH

Co-chairpersons: Raymond N. DuBois, MD, PhD, FAACR, and Richard B. Gaynor, MD

CONTINUING MEDICAL EDUCATION

Chairperson: Nancy E. Davidson, MD

EDUCATION AND TRAINING

Chairperson: Drew M. Pardoll, MD, PhD

FINANCE AND AUDIT

Chairperson: David R. Parkinson, MD
Vice-chairperson: Thomas J. Lynch, Jr., MD

INTERNATIONAL AFFAIRS

Chairperson: Frank McCormick, PhD, FAACR

NOMINATING

Chairperson: Elizabeth H. Blackburn, PhD, FAACR

PUBLICATIONS

Chairperson: Michael A. Caligiuri, MD

SCIENCE EDUCATION

Chairperson: Kathleen W. Scotto, PhD

SCIENCE POLICY AND GOVERNMENT AFFAIRS

Chairperson: William S. Dalton, MD, PhD
Vice-chairpersons: Roy S. Herbst, MD, PhD, and George J. Weiner, MD

SPECIAL CONFERENCES

Chairperson: Ramon E. Parsons, MD, PhD

TELLERS

Chairperson: Danny R. Welch, PhD

Annual Meeting Committees

ANNUAL MEETING PROGRAM

Chairperson: Lewis C. Cantley, PhD, FAACR

ANNUAL MEETING CLINICAL TRIALS

Co-chairpersons: Johann de Bono, MD, PhD, and Patricia M. LoRusso, DO

ANNUAL MEETING EDUCATION

Chairperson: Richard Marais, PhD
Co-chairpersons: Johanna W. Lampe, PhD, David B. Solit, MD, Paul Workman, PhD, and Michael B. Yaffe, MD, PhD

ANNUAL MEETING EXHIBITS

Chairperson: Ethan Dmitrovsky, MD

Scientific Achievement Award Committees

AACR AWARD FOR LIFETIME ACHIEVEMENT IN CANCER RESEARCH

Chairperson: Tom Curran, PhD, FAACR

AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN CHEMISTRY IN CANCER RESEARCH

Chairperson: Lawrence J. Marnett, PhD

AACR CANCER EPIDEMIOLOGY AND PREVENTION AWARDS

Co-chairpersons: John D. Groopman, PhD, and Anil K. Rustgi, MD

AACR-CANCER RESEARCH INSTITUTE LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY

Chairperson: James P. Allison, PhD, FAACR

AACR CLINICAL RESEARCH AND EXPERIMENTAL THERAPEUTICS AWARDS

Co-chairpersons: Susan E. Bates, MD, and William G. Nelson, MD, PhD

AACR DISTINGUISHED LECTURESHIP ON THE SCIENCE OF CANCER HEALTH DISPARITIES

Chairperson: Lisa A. Newman, MD

AACR LABORATORY RESEARCH AWARDS

Chairperson: René Bernards, PhD

AACR MARGARET FOTI AWARD FOR LEADERSHIP AND EXTRAORDINARY ACHIEVEMENTS IN CANCER RESEARCH

Chairperson: Jennifer Rubin Grandis, MD

AACR-MINORITIES IN CANCER RESEARCH JANE COOKE WRIGHT MEMORIAL LECTURESHIP

Chairperson: Rick A. Kittles, PhD

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH

Chairperson: Lisa A. Carey, MD

AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHIP

Chairperson: Lawrence A. Loeb, MD, PhD, FAACR

AACR TEAM SCIENCE AWARD

Chairperson: Paul Workman, PhD

AACR-WOMEN IN CANCER RESEARCH CHARLOTTE FRIEND MEMORIAL LECTURESHIP

Chairperson: Wen-Jen Hwu, MD, PhD

PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH

Chairperson: Joan S. Brugge, PhD, FAACR

LEADERSHIP TASK FORCE CHAIRPERSONS

The AACR shapes the landscape of cancer research through its scientific task forces, convening experts from multiple disciplines to define, evaluate, and foster emerging areas of inquiry. Task forces focus attention and resources on these promising areas, generating a critical mass of interest and discovery to move the field forward.

CANCER EPIGENOME

Chairperson: Peter A. Jones, PhD, DSc, FAACR

MEMBERSHIP DEVELOPMENT

Chairperson: Tyler Jacks, PhD, FAACR



SURGICAL ONCOLOGY

Chairperson: Monica Morrow, MD

LEADERSHIP SCIENTIFIC WORKING GROUP CHAIRPERSONS

When a task force generates a critical mass of interest in an emerging area of research, the AACR promotes further progress in that area by forming scientific working groups. These member groups create communities of interest that build working relationships and foster collaboration.

CANCER IMMUNOLOGY

Chairperson: Pamela S. Ohashi, PhD

CHEMISTRY IN CANCER RESEARCH

Chairperson: David E. Uehling, PhD

MOLECULAR EPIDEMIOLOGY

Chairperson: Jo L. Freudenheim, PhD

PEDIATRIC CANCER

Chairperson: Garrett M. Brodeur, MD



Left to right: Garrett M. Brodeur, MD, incoming chairperson of the Pediatric Cancer Working Group; Lee J. Helman, MD, outgoing chairperson; and Margaret Foti, PhD, MD (hc), AACR CEO.

RADIATION SCIENCE AND MEDICINE

Chairperson: Theodore S. Lawrence, MD, PhD

TUMOR MICROENVIRONMENT

Chairperson: Morag Park, PhD

AACR FOUNDATION

Lauren M. Santarone (right), AACR Senior Meetings Manager, and her sister Kristin (left) at the starting line for AACR Rock 'n' Roll Philadelphia Half-Marathon, held October 31, 2015. AACR staff volunteered at and participated in the race, which raised \$135,000 to support vital AACR initiatives.

AACR FOUNDATION INVESTING IN LIFESAVING CANCER SCIENCE AND MEDICINE

Applying scientific discoveries to improve the lives of cancer patients requires generous financial support from all sectors of the community — from government agencies and nonprofit organizations; from corporate partners; and from patients, caregivers, family, and friends. The AACR Foundation brings these sectors together, directing their varied interests toward the common goal of preventing and curing cancer.

“We are proud to support the work of AACR cancer researchers.”

— Mitchell R. Stoller, AACR Foundation Executive Director

54

Research grants were awarded in 2015.

\$60 million

In donations funded AACR member scientists worldwide.

88 cents

Of every dollar donated to the AACR Foundation supports the lifesaving cancer research of members of the AACR.

Thanks to the efforts of the AACR Foundation and the generosity of its supporters, AACR leadership can make decisions based upon scientific need, investing in emerging areas of research by supporting conferences, projects, and investigators that offer long-term promise as well as immediate impact for patients.

AACR American Association
for Cancer Research
FOUNDATION **FINDING CURES TOGETHER™**





The inaugural recipients of the AACR June L. Biedler Scholar-in-Training Awards were recognized during the opening ceremony at the AACR Annual Meeting 2015.

Honoring the Generosity of June L. Biedler, PhD

In 2015, the AACR launched two programs honoring the memory of June L. Biedler, PhD, a longtime AACR member, a former member of the Board of Directors, and a recipient of the AACR G.H.A. Clowes Memorial Award for outstanding accomplishments in cancer research. Dr. Biedler passed away in 2012, but her contributions to the AACR have continued. In October 2014, her estate made a gift of \$2.5 million to the AACR, the largest bequest in AACR history. The AACR used these funds to establish two new awards:

- In remembrance of her pioneering work in drug resistance, the **AACR June L. Biedler Scholar-in-Training Awards** were established to recognize meritorious proffered papers in this area. The first seven recipients of the award were honored at the AACR Annual Meeting 2015.
- Dr. Biedler was a strong supporter of science communications, and her passion is remembered through the **AACR June L. Biedler Prize for Cancer Journalism**. Announced in 2015, the first prize will be awarded at the AACR Annual Meeting 2016 and will honor outstanding journalistic coverage that enhances the public's understanding of cancer, cancer research, or cancer policy.



Public Education: "The More We Discover Why, The More We'll Know How"

Since its founding in 2000, the AACR Foundation has been a valuable source of cancer research news and information for cancer patients, advocates, and the public. These educational resources were greatly expanded in 2015 as part of the launch of a redesigned Foundation website. In addition to the latest research news, Foundation website visitors can access NCI-approved information on cancer types, learn about clinical trials and recent FDA approvals, and read the personal stories of patients who have benefited from advances in cancer research and of the researchers who made these advances possible.

In 2015, the Foundation launched its first ever marketing campaign to increase public awareness of the AACR and to increase funding for cancer research. The theme of the campaign was summarized by the tagline "The more we discover why, the more we'll know how." The campaign noted that continued progress against cancer depends on better understanding of its complexities, and that the AACR — with the scientific breadth and depth of its members and its ability to foster collaborative relationships — is uniquely positioned to expand that understanding.

The campaign included print, online, radio, television, and billboard advertising in the greater Philadelphia region, in order to maximize awareness of the AACR in its home city. In addition to the new website, the Foundation also reached out globally with an expanded presence on Facebook and Twitter.



Building Community and Relationships: AACR Runners for Research/AACR Rock 'n' Roll Philadelphia Half-Marathon

The AACR Runners for Research program enables individuals, groups, and companies to channel their passion for running toward a common goal of supporting lifesaving cancer research. The AACR Foundation partnered with *runDisney* and the Rock 'n' Roll Marathon Series® to give Runners for Research members opportunities to run in races in more than 25 cities in 2015. The showcase event of this partnership was the AACR Rock 'n' Roll Philadelphia Half-Marathon, held October 31 in the AACR's home city. The AACR was named the charity partner of the event, which raised \$135,000 to fund critical programs.



AACR Industry Roundtable

February 2015 marked the tenth anniversary of this meeting, at which the AACR brings together industry leaders with senior academic scientists and AACR leadership to identify opportunities to advance progress in cancer research. The AACR works with its industry partners on initiatives to expedite advances in the detection, prevention, and treatment of cancer.

AACR Advocacy Partnership Primer

At this inaugural event, held in November 2015, the Foundation brought together patient advocates and representatives from corporations, foundations, and research institutions at the AACR headquarters to engage them in the AACR's advocacy activities and partnership opportunities in support of those activities.



AACR FOUNDATION RESEARCH GRANT FUNDERS

Fostering innovation in cancer science is at the core of the AACR's mission, and research grants support investigators at all career stages to sustain that innovation. The AACR recognizes the following organizations for their vital support of research grants in 2015:

- Aflac, Inc.
- Amgen, Inc.
- Anonymous
- Bayer
- Breast Cancer Research Foundation
- Bristol-Myers Squibb Oncology
- Debbie's Dream Foundation: Curing Stomach Cancer
- Fight Colorectal Cancer
- Genentech BioOncology
- Kure It Cancer Research
- Kirk A. and Dorothy P. Landon Foundation
- John and Elizabeth Leonard Family Foundation
- Michael's Mission
- Neuroendocrine Tumor Research Foundation
- Ocular Melanoma Foundation
- Pancreatic Cancer Action Network
- Stand Up To Cancer
- Triple Negative Breast Cancer Foundation
- Takeda Oncology, Inc.
- The WWWW Foundation, Inc. and the Sarcoma Fund of the QuadW Foundation of Communities Foundation of Texas



Manfred Lehnert, MD (left), Vice President and Head of Innovation at Takeda Pharmaceuticals, congratulates Cindy Lin, PhD (right), recipient of an AACR-Millennium Fellowship in Multiple Myeloma Research. The fellowship encourages and supports a postdoctoral or clinical research fellow to work on mentored multiple myeloma research and to establish a successful career path in this field. Through its partnership with the AACR, Takeda Oncology (formerly Millennium Pharmaceuticals) has provided over \$800,000 since 2013 to support research on hematological malignancies.



Lynn M. Matrisian, PhD, MBA, FAACR (left), Vice President of Scientific and Medical Affairs for the Pancreatic Cancer Action Network, presents a Pancreatic Cancer Action Network-AACR Career Development Award (supported by an anonymous foundation) to Nada Y. Kalaany, PhD (right). The award encourages and supports junior faculty to conduct pancreatic cancer research and to establish successful career paths in this field. Through its partnership with the AACR, the Pancreatic Cancer Action Network has provided over \$27 million since 2003 to support pancreatic cancer research.



Ron Hollander (left), Executive Director of the Neuroendocrine Tumor Research Foundation (formerly the Caring for Carcinoid Foundation), presents the Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research to Scott André Oakes, MD (right). The grant supports independent junior and senior investigators to develop and study innovative new ideas and approaches that have direct application and relevance to carcinoid tumors or pancreatic neuroendocrine tumors. Through its partnership with the AACR, the Neuroendocrine Tumor Research Foundation has provided over \$2 million since 2011 to support carcinoid tumor and neuroendocrine tumor research.

ACKNOWLEDGMENT OF SUPPORTERS

The AACR gratefully acknowledges the individuals and organizations whose 2015 donations are funding pioneering cancer research. Visit AACRFoundation.org to support lifesaving cancer science.



Recipients of the 2015 AACR-Susan G. Komen® Scholar-in-Training Awards at the AACR Annual Meeting. Front row, left to right: Marilyne Kpetemey, BS, Lamiaa El-Shennawy, MS, Christy R. Hagan, PhD, Wing-Yee Lo, PhD. Back row, left to right: Anja Bastian, BS, Zhengyu Jiang, PhD, Tamer S. Kaoud, PharmD, PhD, Daniel L. Abravanel, PhD, Claire I. Vanpouille-Box, PhD. These awards supported early-career investigators who presented meritorious proffered papers relating to breast cancer at the Annual Meeting. Through its partnership with the AACR, Susan G. Komen® has provided over \$9.2 million since 1999 to support breast cancer research.

VISIONARIES

Gifts of \$1,000,000 or more
Entertainment Industry Foundation
Pancreatic Cancer Action Network

INNOVATORS

Gifts of \$100,000 — \$999,999
AbbVie, Inc.
Adelman Trust

Aflac, Inc.
Amgen, Inc.
Anonymous
Anonymous in honor of Dharma Master Jiantai
Astellas Pharma US, Inc.
AstraZeneca
Bayer HealthCare Pharmaceuticals
Boehringer Ingelheim

Breast Cancer Research Foundation
Bristol-Myers Squibb Co.
Celgene Corp.
Debbie's Dream Foundation:
Curing Stomach Cancer
Eli Lilly and Company
Genentech BioOncology
Gilead Sciences, Inc.
Janssen Research and Development, LLC
Kirk A. and Dorothy P. Landon Foundation
Kure It Cancer Research
Merck and Co.
Neuroendocrine Tumor
Research Foundation
Novartis Institutes for BioMedical Research
Pfizer, Inc.
Susan G. Komen
Takeda Oncology
Triple Negative Breast Cancer Foundation
The WWWW Foundation Inc. and
The Sarcoma Fund of the QuadW
Foundation of Communities Foundation
of Texas

LAUREATES

Gifts of \$10,000 — \$99,999

Alzheimer's Association
American Cancer Society
Ash Stevens, Inc.
Astex Pharmaceuticals, Inc.
BioMarin Pharmaceutical, Inc.
Cancer Research Institute
John S. Cargile, MD
Virginia and Bayard D. Clarkson,
MD, FAACR
Colon Cancer Alliance
Eisai Research Institute

Fight Colorectal Cancer
Margaret Foti, PhD, MD (hc)
Get Your Rear In Gear Philadelphia,
supported by the Colon Cancer Coalition
Wayne Griswold
Illumina, Inc.
Incyte Corporation
Irving Weinstein Foundation
Janssen Biotech, Inc.
John and Elizabeth Leonard
Family Foundation
Jose Pepper's Restaurants
Kelly Golat Melanoma Research and
Scholarship Fund
Estate of Vera M. Kirkland
Marion A. Nichol Family By-Pass Trust
Marsha Rivkin Center for Ovarian
Cancer Research
Mary Jean Dresie Trust
Michael's Mission
Ocular Melanoma Foundation
Pezcoller Foundation
Pharmaceutical Research and
Manufacturers of America
Princess Takamatsu Cancer Research Fund
Research!America
Rose A. Sinkin Trust
Rosenthal Family Foundation
Sanofi
Charles L. Sawyers, MD, FAACR
Seattle Genetics, Inc.
Servier
Taiho Pharmaceutical Co.
Tang Family Foundation
Theradex Systems, Inc.
Sidney Kimmel Cancer Center at
Thomas Jefferson University

United Way of Central Maryland
United Way of Greater Philadelphia and
Southern New Jersey
University of Minnesota Physicians
William H. Prusoff Foundation

FOUNDERS

Gifts of \$5,000 — \$9,999

AdvaMedDx
American Heart Association
American Society of Clinical Oncology
Anonymous
Hilda and Carlos L. Arteaga, MD, FAACR
Association of American Medical Colleges
José Baselga, MD, PhD, FAACR
BD Co.
Robert Bruce Church
Clarity Foundation
Coalition for the Life Sciences
Cathy Fraser
Gordon and Margaret Bailey Foundation
Brian D. Henry
Hydrocephalus Association
Jay Klein
Ludwig Cancer Research Institute
Microsoft Giving Campaign
Moffitt Cancer Center and Research Institute
Prostate Cancer Foundation
Rodney H. and Judy E. Margolis Foundation
Società Italiana di Cancerologia
Subaru of America Foundation
Stephen D. Ryan
Transamerica Life Insurance Company
Ann L. and Daniel D. Von Hoff,
MD, FAACR

INVESTIGATORS

Gifts of \$2,500 — \$4,999

Beverly and Stu Aisenbrey
Mary Baudino
Oliver Bogler, PhD
Jessica C. Burgess
Charles River Laboratories, Inc.
Dana-Farber Cancer Institute
Lisa and Raymond N. DuBois,
MD, PhD, FAACR
Scott Gorman
Teri Griege
Johnson and Johnson Matching
Gifts Program
V. Craig Jordan, OBE, PhD, DSc, FAACR
Eleanor D. Kress
Natalina B. and Charles D. Lunsford
Patricia and William H. Mears Jr., JD
John E. Oxendine, MBA
PHL Diversity
Linda Roe
Poonam Seghal, MD and
Anil Rustgi, MD, PhD
Laura K. Shawver, PhD
Howard E. Shulman
Michael J. Skibicki
Sheri and Mitch Stoller
Estate of Eleanor Tepfer
United Way of Allegheny County
University of Texas MD Anderson
Cancer Center
Weill Cornell Medical College of
Cornell University
Wells Fargo Community
Support Campaign
Wilfred Sloane Foundation

BENEFACTORS

Gifts of \$1,000 — \$2,499

Aetna Foundation
Dana T. Aftab, PhD
Alliance for Aging Research
ALS Association
American Association of
Colleges of Nursing
American Association of Immunologists
American Lung Association
American Society of Hematology
ArcelorMittal Matching Gifts Program
Association of American Cancer Institutes
Doreine Carson Beck and
William T. Beck, PhD
Mary Beckerle, PhD
Maggie May Bell
Joseph R. Bertino, MD, FAACR
Pradeep Bethi
Frédéric Biemar, PhD
Biophysical Society
Clara D. Bloomfield, MD
William J. Blot, PhD
Lori Ann Brummer
Natasha Bunin
Richard T. Burke
Michael Caligiuri, MD
Lewis C. Cantley, PhD, FAACR
Minh Xuan Pham Cao
Jasmine Cheeves
Katie Cohen
Columbia University Medical Center
Dana Conroy
Amanda Darcy
Deep South Crane and Rigging, LLC
George Demetri, MD
Endocrine Society

Debbie Espinosa
EveryLife Foundation for Rare Diseases
Kit Farwell
Federation of American Societies for
Experimental Biology
Genevieve Fisanich
Maria Fitzpatrick
Faye Florence
James M. Ford, MD
Frederic W. Cook and Co., Inc.
Elizabeth Fuller
Matthew Funk
Myles Brown, MD and
Judy E. Garber, MD, FAACR
Kari and Mike Gedville
Genomic Health, Inc.
Marissa Gernett
Gibson Partners
Tona M. Gilmer, PhD
Give with Liberty
GlaxoSmithKline Foundation
Molly Goldman
Josh Goldstein
Marilyn B. Hirsch and
Gary B. Gordon, MD
Jack Gorman
Graycor Project Team
Charlotte Griffith
Sung and William N. Hait,
MD, PhD, FAACR
Joseph Harris
Hats with Heart
Deann M. Hawley
Bobbi-Jo Hays
Stephen S. Hecht, PhD
Julie and Bayard Henry
Susan Band Horwitz, PhD, FAACR

ACKNOWLEDGMENT OF SUPPORTERS

Mike Hsu
 Jamie Huemme
 Jenny Price and Tony Hunter, PhD, FAACR
 Wen-Jen Hwu, MD, PhD
 Hydro Angels Over America
 Irving S. and Alwyn N. Johnson Family
 Foundation, Inc.
 Jennifer Reiko Ishii
 Dana Ivanco
 Elizabeth Jaffee, MD
 Jean and Saul A. Mintz Foundation
 Peter A. Jones, DSc, PhD, FAACR
 Joanna Jurich
 Phyllis and Donald Kahn
 Sheryl Kaitz
 Christine Katt
 Keith Kaufman
 Nancy Davidson, PhD and
 Thomas Kensler, PhD
 Robert Kent
 Lark Killelea
 Randy Kim
 Melissa Kelli Kindelspire
 Elizabeth Knox
 KPMG
 Ashley Krasucki
 Mark Lachance
 Luke K. Lam
 Kara Landrigan
 April Mercado Licup
 LIVESTRONG Foundation
 Phyllis and Lawrence Loeb,
 MD, PhD, FAACR
 Tat Luong
 Richard Marais, PhD
 Elaine Mardis, PhD
 Lawrence J. Marnett, DPhil

Connie J. Marshall
 Marlene and Laurence J. Marton, MD
 Armah Mason
 Merck Foundation
 Irene and Michael L. Meyers, MD, PhD
 Rachel Meyrowitz
 Arthur Mistretta
 Vern Mitchell
 Alicia Claire Montgomery
 Annette Moreira
 Caterina L. Musetti, PhD
 National Alliance for Eye and
 Vision Research
 National Multiple Sclerosis Society
 Nancy Ann Nye-Grindey
 Martha Darling and
 Gilbert S. Omenn, MD, PhD
 Dorselda Parker
 Sara Parkinson
 Pfizer United Way Campaign
 George C. Prendergast, PhD
 Sarah Elizabeth Presley
 Jannet L. Preti
 Susan and Kanti Rai, MBBS, MD
 Sujaya Rao
 Autumn J. Re
 Mike Reinero
 Lisa Romanzo
 Todd Rudo
 St. Baldrick's Foundation
 Scott K. Sakakihara
 Kevin Schneider
 Marilyn and Alan Schwedel
 John A. Secrist, III, PhD
 SEIU Local 1199
 Lynn Seuberling
 Morgan Alexandra Shepard

Charles J. Sherr, MD, PhD, FAACR
 Kristen Shoemaker
 Keith Smith
 Eric J. Stanbridge, PhD
 John Stevens, MD
 Ariel Stevenson
 Cathy and Mike Stewart, MBA
 Paul Stierer
 Kalina J. Stogsdill
 Brenda Swiney
 Kheng Tan
 Travelers Insurance
 Tremor Action Network
 William Tunno
 Laura Tyson, PhD
 United Way of the Greater Lehigh Valley
 University of Kansas Cancer Center
 University of New Mexico Cancer Research
 and Treatment Center
 University of Pittsburgh Cancer Institute
 and UPMC Cancer Center
 US Raceworks LLC
 Dominic Valdez
 George F. Vande Woude, PhD, FAACR
 Christine Viento
 Barbara Parker-Wahl, MD, and
 Geoffrey Wahl, PhD, FAACR
 James D. Watson, DSc, PhD, FAACR
 Vivian Weinberg, PhD
 Christopher White
 Gerald Wogan, PhD
 Robert C. Young, MD
 Raymond W. Yue
 Eleanor H. and Stuart H. Yuspa, MD
 Valerie Zara

CHALLENGERS**Gifts of \$500 — \$999**

A2Q2
 Sami Alagic
 Allstate Giving Campaign
 John Alpizar
 Amanda Alsbrook
 Kenneth C. Anderson, MD,
 PhD (hc), FAACR
 Susan Angelo
 Anonymous
 Estate of Charles Herman Armstrong
 AT&T United Way Employee
 Giving Campaign
 Authority Partners, Inc.
 Wendy Baake
 Hilary Baldwin
 Blair Bales
 Anastacia R. Banke
 Diane Bartone
 Hannah Beldyga
 Lisa K. Bell
 Judith Bishop
 Luis Blanco
 Christi Bluemle
 Christa Braun-Inglis
 Briarcliff Congregational Church
 Women's Society
 Samantha Bronfman
 Christine M. Brown
 Thomas Brownlee
 Jennifer Bruder
 Jason Campbell
 Edison Cirino Capelo
 Kaela Cashman
 Webster Cavenee, PhD, FAACR
 Linda Chilvers

Jill Ciavatta
 Camille Ciesliga
 Michelle Coborn
 Brian Costello
 Kathy Couch
 Catherine Coughlin
 Michael Dale
 Nancy Jean DeGennaro
 Maggy D'Onofrio
 Double J Dairy
 Anita Dudek
 Veronica A. Dunaway
 Henry Dunlop
 Dan Eldredge
 Ekman Recycling
 Leigh Ann Farmer
 Charlie Fink
 Frank Flaherty
 Evelin Flores
 Steven Folkers
 Ruth Fortson
 Jarod Fox
 Tricia Francisco
 Ivan Garcia
 GenScript USA, Inc.
 Crystal Giedt
 Linda and Mike Gilbert
 Beth Goshow
 Melissa Gruber
 Jordan Hall
 Kathleen Hall
 Anne Harney
 Dawn Harty-Schmitt
 David Hays
 Andrew Helffrich
 Erika Hennings
 Luis Hernandez

Ryan Horst
 Barb Hujsa
 Kathryn Hunchar
 Phillip Ippolito
 Bonnie L. Johnson
 Bryan R. Johnson
 Marquel S. Jordan
 Sarah M. Jordan
 Just a Cut Away Barber Salon
 Lou Kaelin
 Beth Karchner
 Judith E. Karp, MD
 Michael Kastan, MD, PhD
 Christopher Kelly
 Aubrey King
 Eric Kirsch
 Chrissy Kissinger
 Nancy E. Kohl, PhD
 Paula Kowalczyk
 Phillip Kraft, PhD
 Gerry Lui Kuo
 Jack Kutney
 Tim Lawrence
 Laura S. Legner
 Carol Lissack
 Betty Lok-Johnson
 Francesca Longo
 Guillermina Lozano, PhD
 Jennifer Low, MD, PhD
 Laura Maddox
 Danuta Malejka-Giganti, PhD
 Margarita Martinez
 Maggie Martins
 Jessica Mason
 Adam Zachary McClain
 Justin McColgan
 Lisa McGlashen

Kelsey McGuigan
 Robert and Elizabeth Mennel
 Claudia Monserrat
 Jaime Monserrat
 Harriet Morgan
 Morgan Stanley Annual Appeal Campaign
 Joanne Mullen
 Catherine Murray
 Dana Myers
 Rebecca Nazario
 David John Neven
 Elizabeth Ann Neven
 Don Nishioka
 J. Kay Noel, PhD
 Northwest R-I School District
 Anna Nocas
 Brett O'Hara
 Allison Bailey Olson
 Kristen Papenberg
 Tina Patel
 Nancy Perry
 Roy Pierson
 Kerry Pigott
 Joseph Pride
 Prudential Foundation
 Matching Gifts Program
 James Putnam
 Linda Ridolfi
 Jon Robins
 Robert Romero
 Petra Rose
 Joy K. Rouse
 Lauren Santarone
 Robert Savannah
 Alissa Schwartz
 City of Seattle
 Marc A. Sessa

Maya Seunarine
 Patrick Shanahan
 Silicon Valley Community Foundation
 Brendan Skwire
 Elaine L. Spotswood
 James Stenger
 Lynn Sullivan
 Natalie Sutherland
 Brenda Swiney
 Ryan Tarapchak
 Robin Taylor
 Jay Te Velde
 Geoffrey Temple
 Holly J. Tinter
 Nicole M. Ulrey
 United Way of Central New Mexico
 United Way of the National Capital Area
 Robert Utter
 Deborah Van Dam
 Victor E. Velculescu, MD, PhD
 Tiffany Walser
 Waterford Group Charitable Foundation
 Hallie Weakland
 Kim Weisberg
 Meredith Willenbring
 Joshua Winikoff
 Owen N. Witte, MD, FAACR
 Linda Wollberg
 Wonderful Giving
 Nick Yando
 DeeAnn Yabusaki
 Mark J. Yaney
 Linda Yosten
 Yumi Yun
 Debbie Zellers


FINANCIAL STATEMENT

In 2015, the AACR reported another year of positive financial growth. This financial stability enables the AACR to comprehensively meet the challenges of the cancer problem. Operating revenues increased 6 percent to \$80 million and total expenditures closely matched revenues. The net impact of revenues and expenses resulted in an operating surplus of \$708,000. As outlined in this report, several major projects were launched in 2015, and the AACR was able to outperform the budget through successful programming, revenue growth, and prudent financial management.


Non-operating activities are primarily related to long-term investments. After six straight years of positive performance in the AACR's investment portfolio, the market corrected in 2015 and the portfolio experienced negative returns in the amount of \$2.2 million. These returns were partly offset by the net operating surplus, resulting in an overall net deficit of \$1.5 million for the year. At the end of 2015, the AACR had unrestricted net assets of \$55 million, which ensures continued investment in the programs that will accelerate progress toward the prevention and cure of cancer.

AACR FINANCIAL STATEMENT REVENUES AND EXPENSES 2015

2015 TOTAL EXPENSES



2015 PROGRAM EXPENSES



American Association for Cancer Research, Inc. and AACR Foundation Unrestricted Revenues and Expenses (Unaudited) AS OF DECEMBER 31, 2015

	2014	2015	2015 PERCENT OF TOTAL
REVENUE			
Membership Dues	\$2,930,621	\$3,196,495	4%
Scientific Publishing	\$16,805,827	\$16,663,104	21%
Scientific Meetings / Educational Workshops	\$15,356,680	\$20,796,899	26%
Other Revenue	\$499,422	\$750,426	1%
Subtotal: Program Revenue	\$35,592,550	\$41,406,924	52%
Support			
NIH Grants	\$820,597	\$872,051	1%
Contributions	\$39,202,836	\$38,105,375	47%
Subtotal: Support Revenue	\$40,023,433	\$38,977,426	48%
TOTAL REVENUE	\$75,615,983	\$80,384,350	100%

EXPENSES			
Research Grants / Scientific Awards	\$30,930,096	\$31,379,839	39%
Scientific Meetings / Educational Workshops	\$14,762,461	\$18,542,272	23%
Scientific Publishing	\$11,094,165	\$10,736,399	13%
Communications / Science Policy / Patient Education	\$5,833,030	\$7,195,979	9%
Professional Education / Scientific Programs	\$1,782,654	\$2,852,769	4%
Subtotal: Program Expenses	\$64,402,406	\$70,707,258	89%
Support Services	\$6,225,968	\$5,412,872	7%
Fundraising / Development	\$2,460,464	\$3,555,983	4%
Subtotal: Support Expenses	\$8,686,432	\$8,968,855	11%

TOTAL EXPENSES	\$73,088,838	\$79,676,113	100%
Operating Surplus before Investments	\$2,527,145	\$708,237	
Investment Income	\$2,372,739	(\$2,210,636)	
Change in Unrestricted Net Assets	\$4,899,884	(\$1,502,399)	
NET ASSETS BEGINNING OF YEAR	\$51,998,173	\$56,898,057	
NET ASSETS END OF YEAR	\$56,898,057	\$55,395,658	

SHAPING THE FUTURE OF CANCER RESEARCH

Strategic Planning: Building the Foundation of the Cancer Research Enterprise

During the past year, the AACR Board of Directors led a forward-looking initiative to develop a Vision 2020 Strategic Plan for the organization. This planning initiative set goals for markedly reducing cancer incidence and mortality, established scientific priorities to support those goals, and defined the AACR programs that will support those priorities in 2016 and beyond.

Vision 2020: A Roadmap for Growth and Impact – Strategic Goals

- To identify and foster innovative science that is of the highest priority and potential for impact in reducing cancer incidence, morbidity, and mortality.
- To become the primary educational resource for cancer scientists, the broader biomedical science community, and the public.
- To publish and disseminate high-quality cancer science worldwide.
- To meet the professional needs of members and increase international outreach and participation.
- To increase awareness of the AACR among the public.
- To serve as the authoritative voice for cancer research and thereby inform and influence science and public policy.

- To develop and implement a comprehensive financial plan that supports the strategic plan and achieves dynamic growth and increased impact.

AACR Provides Thought Leadership to Biden's New Initiative to Accelerate Cancer Research

In 2015, the government's efforts to find a cure for cancer were reinvigorated. The National Cancer Institute (NCI) received its largest annual appropriations increase in 12 years (for FY 2016), and Vice President Joe Biden — still mourning the death of his son, Beau, from brain cancer — called for an “absolute national commitment to end cancer as we know it today.”

Within the first few days of 2016, AACR President José Baselga, MD, PhD, FAACR, led a group of 15 distinguished AACR members from 10 of the top cancer centers and medical institutions representing nine states to meet with Biden's senior staff and discuss the state of cancer research. These AACR experts, comprised of AACR Board Members and other AACR leaders, offered insight into priorities that could help achieve the vice president's vision of “making a decade's worth of advances in five years.” Just days later, during his 2016 State of the Union Address, President Obama formally announced a national effort to be led by Biden to develop new treatments for cancer.



Prestigious leaders of the AACR were again called upon a few weeks later to provide their expertise. Biden invited three presidents and Fellows of the AACR — Baselga, Charles L. Sawyers, MD, and Elizabeth Blackburn, PhD — to provide their thoughts and guidance at a special session at the World Economic Forum in Davos, Switzerland. Vice President Biden highlighted the importance of data-sharing initiatives during the session and cited AACR Project GENIE (see pg. 60) during his opening remarks.

Since then, Biden continues to visit cancer centers across the country to learn about the latest innovations and hear first-hand perspectives from cancer researchers and physician scientists — many of whom are AACR leaders and members — about how to propel cancer research forward.

As this national effort continues to gain momentum, the AACR will work collaboratively alongside all stakeholders in the broader cancer research and care community to help chart a course with the goal of conquering the more than 200 diseases we call cancer.

AACR programs and initiatives have fostered collaboration, sparked innovation, and driven progress against cancer in the past year. In 2016, the AACR is taking bold steps to continue that progress by transforming the landscape and expanding the frontiers of cancer science.



THE AACR IN 2016: A LOOK AHEAD

Project GENIE: Sharing Data to Catalyze Precision Oncology

In November 2015, the AACR announced the launch of Project GENIE (Genomics, Evidence, Neoplasia, Information, Exchange). AACR Project GENIE is a multi-phase, international data sharing project that will link cancer genomic data with clinical outcomes from tens of thousands of cancer patients into a registry that will improve clinical decision-making and catalyze clinical and translational research.



Project GENIE is the brainchild of AACR Past President **Charles L. Sawyers, MD, FAACR**. The AACR is the project lead, housing the Coordinating Center and providing the seed money necessary to launch phase I. After a period of exclusivity, all project data will be made publicly available (starting with an initial release in November 2016) to benefit cancer patients everywhere.

By linking genotypes to clinical outcomes, the data from project GENIE will help clinicians answer a range of clinical questions:

- **Validating Biomarkers.** Pooled genotype-phenotype relationships can confirm or refute that specific mutations can predict patient responses to drugs.
- **Repurposing Drugs.** A mutation in a specific cancer type could be identified in other cancer types, suggesting that drugs approved for one cancer may be effective against others. Conversely, a drug that is approved for patients with a particular mutation can be evaluated to determine whether it could successfully treat patients with a different mutation.
- **Exploring Rare Cancers.** The GENIE registry will ultimately provide the “critical mass” of data necessary to achieve the statistical power needed to support treatment decisions for rare cancers and rare variants in common cancers.

AACR Project GENIE: Founding Members

Phase 1 Participants

- The Center for Personalized Cancer Treatment, Utrecht, Netherlands
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Institut Gustave Roussy, Villejuif, France
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

- Memorial Sloan Kettering Cancer Center, New York, New York
- Princess Margaret Cancer Centre, Toronto, Canada
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Informatics Partners

- Sage Bionetworks, Seattle, Washington
- cBioPortal, New York, New York

Think Tank: Shaping the Future of Cancer Prevention – A Roadmap for Integrative Cancer Science and Public Health

Throughout its proud history of setting the research agenda for the cancer community, the AACR has been instrumental in making cancer prevention a major focus of that agenda. From the prohibition of smoking in session rooms (1969) to the first major session on prevention (1979) to the presentation of the AACR-ACS Award for Research Excellence in Cancer Epidemiology and Prevention (1992), the AACR Annual Meeting has provided a forum for pioneering cancer prevention science. As the needs of the field have expanded, the AACR has acted boldly to meet those needs – establishing a multidisciplinary journal with a focus on prevention (*Cancer Epidemiology, Biomarkers & Prevention*, 1991), creating the first major annual meeting devoted to Frontiers in Cancer Prevention (2002), and launching the first scientific journal dedicated exclusively to cancer prevention from preclinical research to clinical trials (*Cancer Prevention Research*, 2008).

The field of cancer prevention is at an exciting stage, and once more the AACR is taking the lead to define how integrative cancer prevention science can best support public health. An AACR Think Tank was held in February 2016 to discuss and shape the future of the many fields that comprise cancer prevention. Chaired by



Ernest T. Hawk, MD, MPH (left), and **Scott M. Lippman, MD (right)**, this meeting convened all stakeholders in the cancer prevention arena to define the past, present, and future of cancer prevention and to determine how the AACR can support the evolution of cancer prevention and improved patient care.

Noncoding RNAs represent a diverse family of regulatory transcripts that affect every stage of gene expression, from transcription and mRNA stability to mRNA translation. Recent evidence has uncovered critical roles for noncoding RNAs in cancer pathogenesis. Artistic interpretation of noncoding RNAs for the AACR Special Conference on Noncoding RNAs and Cancer, December 4-7, 2015, Boston, Massachusetts